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1. INTRODUCTION 
 
Despite the fact that significant advancements have been made in the 
development of well-designed systems to modify the oral delivery of drugs, the 
fundamental approaches have remained largely unchanged with the major systems being 
(a) insoluble matrix, (b) slowly eroding matrix, (c) swelling matrix, (d) polymer-coated 
tablets, (e) polymer coated pellets or granules, (f) osmotically driven systems, (g) systems 
controlled by ion exchange mechanisms, and (h) various combinations of these 
approaches. The scientific literatures are filled with new convoluted examples of oral 
modified-release systems, but the commercial applicability and success of many of these 
systems has to be realized.  
Over the past 20 years, advances in oral modified-release technologies have been 
largely driven by substantial improvements in manufacturing equipment, most notably 
coating equipment, as well as the development of improved biocompatible and 
biodegradable polymeric materials for controlling release rates. A further driving force 
has been the development of a greater appreciation by both pharmaceutical scientists and 
regulatory authorities of the impact of physiological variability on the performance of 
modified-release products leading to more stringent requirements to ensure their safety 
and efficacy. The formulation of an enteric-coated product in the form of small 
individually enteric-coated granules or pellets (multi-particulates) contained in a rapidly 
dissolving hard gelatin capsule or a rapidly disintegrating tablet, largely eliminates the 
dependency of this type of dosage form on the all-or-nothing gastric emptying process 
associated with intact (monolith) enteric coated tablets. Provided the coated granules or 
pellets are sufficiently small (less than 1 mm diameter), they will be able to empty from 
the stomach with liquids. Hence enteric-coated granules and pellets exhibit a gradual but 
continual release from the stomach into the duodenum. This type of release also avoids 
the complete dose of drug being released into the duodenum, as occurs with an enteric-
coated tablet. The intestinal mucosa is thus not exposed locally to a potentially toxic 
concentration of drug (28).  
Historically, the term pellet has been used by a number of industries to describe a 
variety of agglomerates produced from diverse raw materials, using different pieces of 
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manufacturing equipment. In the pharmaceutical industry, pellets can be defined as small, 
free-flowing, spherical particulates manufactured by the agglomeration of fine powders 
or granules of drug substances and excipients using appropriate processing equipment. 
The term also has been used to describe small rods with aspect ratios of close to unity. 
Although pellets have been used in the pharmaceutical industry for more than 4 decades, 
it has only been since the late 1970s, with the advent of controlled-release technology, 
that the advantages of pellets over single-unit dosage forms have been realized.  
Pellets offer a high degree of flexibility in the design and development of oral 
dosage forms. They can be divided into desired dose strengths without formulation or 
process changes and also can be blended to deliver incompatible bioactive agents 
simultaneously and/or to provide different release profiles at the same or different sites in 
the gastrointestinal (GI) tract. In addition pellets taken orally, disperse freely in the GI 
tract, maximize drug absorption, minimize local irritation of the mucosa by certain 
irritant drugs, and reduce inter and intra-patient variability. 
Given the enormous advantages of multiparticulate systems over single-unit oral 
dosage forms, extensive research has focused recently on refining and optimizing existing 
pelletization techniques as well as on the development of novel manufacturing 
approaches that use innovative formulations and processing equipment. The most 
commonly used and intensely investigated pelletization processes are powder layering, 
solution/suspension layering, and extrusion–spheronization (2)  
1.1 POWDER LAYERING 
Powder layering involves the deposition of successive layers of dry powder of 
drug or excipients or both on preformed nuclei or cores with the help of a binding liquid. 
Because powder layering involves the simultaneous application of the binding liquid and 
dry powder, it generally requires specialized equipment.  
The first equipment used to manufacture pellets on a commercial scale was the 
conventional coating pan, a machine that has been used by pharmaceutical firms, 
primarily for sugar coating, for a long time. Conventional coating pans, however, have 
had significant limitations as pelletization equipment. The degree of mixing is very poor, 
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and the drying process is not efficient. Mixing is a function of the pan shape, the tilt 
angle, the baffle arrangement, and the rotational speed of the pan itself. These parameters 
must be optimized to provide uniform drying and sufficient particle movement to 
eliminate the potential formation of dead spots during the operation and to maximize 
yield. For instance, during pelletization, elliptical pans tend to have fewer stagnant spots 
than do cylindrical pans and, consequently, are the equipment of choice. Reducing the tilt 
angle can also minimize formation of dead spots. If the rotational speed of the pan is too 
slow, segregation may occur owing to percolation and induce the preferential layering of 
drug onto larger particles. In addition, prolonged contact time among the particles could 
favor particle agglomeration if the liquid feed rate leads to surface wetness and stickiness 
that induce coalescence.  
During powder layering, a binding solution and a finely milled powder are added 
simultaneously to a bed of starter seeds at a controlled rate. In the initial stages, the drug 
particles are bound to the starter seeds and subsequently to the forming pellets with the 
help of liquid bridges originated from the sprayed liquid. These liquid bridges are 
eventually replaced by solid bridges derived either from a binder in the application 
medium or from any material, including the drug substance, that is soluble in the liquid. 
Successive layering of the drug and binder solution continues until the desired pellet size 
is reached. Throughout the process, it is extremely important to deliver the powder 
accurately at a predetermined rate and in a manner that maintains equilibrium between 
the binder liquid application rate and the powder delivery rate. If the powder delivery rate 
is not maintained at predetermined equilibrium levels, over wetting or dust generation 
may occur, and neither the quality nor the yield of the product can be maximized. Toward 
the end of the layering process, it is likely that fines may be generated owing to potential 
interparticle and wall-to-particle friction and appears in the final product, thereby 
lowering the yield. The problem can be overcome if the application medium is sprayed 
on the cascading pellets at the end of the layering process to increase the moisture level at 
the pellet surface and facilitate layering of the fines onto the pellets. In an ideal process, 
no agglomeration occurs, and the particle population at the end of the process remains the 
same as that of the starter seeds or cores, with the only difference being an increase in the 
size of the pellets and thus in the total mass in the pan.  
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Fig, 1 Schematic representation of centrifugal fluid bed equipment and 
process with a single walled product chamber. A) Glatt GPCG and GRG 
Granulators and B) Freund CF Granulators.   
Pieces of equipment that overcame the limitations of coating pans and 
revolutionized powder-layering processing as a pelletization technique are tangential 
spray or centrifugal fluid-bed granulators. Although tangential spray equipment was 
originally developed to perform granulation processes, its application was later expanded 
to cover other unit operations including the manufacture and coating of pellets.  
Although there are variations in the design of centrifugal or rotary granulators, the 
basic operational principle that determines the degree of mixing and thus the efficiency of 
the process remains the same and includes centrifugal force, fluidization air velocity, and 
gravitational force (Fig. 1).During a layering process, these three forces act in concert to 
generate a spiral, rope-like motion of the particles in the product bed. The rotating disk, 
which may have fixed or variable speeds, creates a centrifugal force that pushes the 
particles outward to the vertical wall of the product chamber or stator. The fluidization 
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air, which is directed toward the slit between the periphery of the disk and the stator, 
generates a force that carries the particles vertically along the wall of the product 
container into the expansion chamber. The particles lose their momentum and cascade 
down toward the center of the rotating disk owing to gravitational force. The cycle 
repeats itself, bringing about a thorough mixing unparalleled by any other powder-
layering equipment. The degree of mixing depends on the fluidization air volume and 
velocity, the slit width, the bed size, and the disk speed. These variables, as well as liquid 
and powder application rates, atomization air pressure, fluidization air temperature, and 
degree of moisture saturation determine the yield and quality of pellets.  
1.2 SOLUTION / SUSPENSION LAYERING 
Solution/suspension layering involves the deposition of successive layers of 
solutions and/or suspensions of drug substances and binders on starter seeds, which may 
be inert materials or crystals/granules of the same drug. In principle, the factors that 
control coating processes apply to solution or suspension layering and, as a result, require 
basically the same processing equipment. Consequently, conventional coating pans, fluid 
bed centrifugal granulators, and Wurster coaters have been used successfully to 
manufacture pellets. The efficiency of the process and the quality of pellets produced are 
in part related to the type of equipment used.  
The Wurster coating process, which was invented about 30 years ago, had 
evolved through elaborate design modifications and refinement into ideal equipment for 
the manufacture of pellets by solution/ suspension layering. The high drying efficiency 
inherent in fluid-bed equipment, coupled with the innovative and efficient design features 
of the Wurster process, has allowed the machines to hold center stage in pharmaceutical 
processing technology. 
 The primary features that distinguish Wurster equipment from other fluid-bed 
equipment are the cylindrical partition located in the product chamber and the 
configuration of the air distributor plate, also known as the orifice plate (Figs. 2 and 3). 
The latter is configured to allow most of the fluidization or drying air to pass at high 
velocity around the nozzle and through the partition, carrying with it the particles that are 
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being layered on. Once the particles exit the partition, they enter the expansion chamber, 
where the velocity of the air is reduced below the entrainment velocity, and the particles 
fall back to the area surrounding the partition (referred to as the down bed). The down 
bed is kept aerated by the small fraction of air that passes through the small holes on the 
periphery of the orifice plate.  
 
 
 
 
 
 
 
 
 
Fig. 2 Schematic representation of the Wurster product chamber and 
process. (A) Product Chamber, (B) Partition, (c) Orifice Plate, (D) Nozzle and E) 
Expansion Chamber. 
          The particles in the down bed are transported horizontally through the gap between 
the air distributor plate and the partition by suction generated by the high air velocity that 
prevails around the nozzle and immediately below the partition. The volume of air that 
passes through the down bed outside the partition is just enough to generate modest 
particle movement. Because the spray direction is concurrent with particle movement, 
and particle motion is well-organized under optimum conditions, uniform layering of 
drug substances is consistently achieved. Because the partition height, that is, the gap 
between the partition and the orifice plate, controls the rate at which the particles enter 
the spray zone, it is an important variable that needs to be optimized for every batch size.  
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Fig. 3 Air Distributor or Orifice Plate of a Wurster Coater 
          The disadvantage of the Wurster process is the inaccessibility of the nozzles. If the 
nozzles are clogged at any time during the layering process, the operation has to be 
interrupted, and the spray guns must be removed for cleaning. The problem can be 
alleviated by screening the formulation or by using a spray gun with a bigger nozzle. 
Another aspect of the process that is challenging when multiple nozzles are used is the 
potential overlap of adjacent spray zones. Although the position of the nozzle is fixed, the 
spray zone overlap can be minimized using the air cap at the end of the spray gun.  
 Solution/suspension layering is usually used when the desired drug loading of the 
pellets is low because production of high-potency pellets from a low solids content 
formulation is not economically feasible. An important factor that needs to be considered 
when suspensions are used as opposed to solutions is the particle size of the drug. 
Micronized drug particles tend to provide pellets that are smooth in appearance, a 
property that is extremely desirable during subsequent film coating, particularly for 
controlled-release applications. If the particle size of the drug in the suspension is large, 
the amount of binder required to immobilize the particles onto the cores will be high, and, 
consequently, pellets of low potency are produced. The morphology of the finished 
pellets also tends to be rough and may adversely affect the coating process and the coated 
product. Moreover, because particles detach easily from the core they are being layered 
on owing to frictional forces, yield is usually low.  
Although it is possible to manufacture pellets from a formulation that does not 
contain binders, almost invariably, the layers of drug applied tend to delaminate or break 
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off from the cores in the later stages of the layering process or in the subsequent drying 
step. Therefore, binders are consistently used during solution/suspension layering to 
impart strength to the pellets. They are usually low-molecular-weight polymers that are 
compatible with the drug substance. 
They should not increase the viscosities of the formulations appreciably and 
should not, unless intended to do so, modify the release characteristics of the pellets.  
1.3 EXTRUSION–SPHERONIZATION 
For some applications it may be desirable to have a dense, spherical pellet of the 
type difficult to produce with the equipment above. Such pellets are used for controlled 
drug release products following coating with a suitable polymer coat and filling into hard 
gelatin capsules. Capsule filling with a mixture of coated and non-coated drug-containing 
pellets would give some degree of programmed drug release after the capsule shell 
dissolves. A commonly used process involves the separate processes of wet massing, 
followed by extrusion of this wet mass into rod-shaped granules and subsequent 
spheronization of these granules. Because this process is used so frequently to produce 
modified release multiparticulate. 
Extrusion–spheronization is a multistep process involving dry mixing, wet 
granulation, extrusion, spheronization, drying, and screening. The first step is dry mixing 
of the drug and excipients in suitable mixers followed by wet granulation, in which the 
powder is converted into a plastic mass that, can be easily extruded. The extruded strands 
are transferred into a spheronizer, where they are instantaneously broken into short 
cylindrical rods on contact with the rotating friction plate and are pushed outward and up 
the stationary wall of the processing chamber by centrifugal force. Finally, owing to 
gravity, the particles fall back to the friction plate, and the cycle is repeated until the 
desired sphericity is achieved (20). 
Extrusion–spheronization as a pelletization technique was developed in the early 
1960s and since then has been researched and discussed extensively. The technology is 
unique in that it is not only suitable for the manufacture of pellets with a high drug 
loading but it also can be used to produce extended release pellets in certain situations in 
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a single step and thus can obviate the need for subsequent film coating. A variety of 
extruders, which differ in design features and operational principles, are currently on the 
market and can be classified as 1) Screw-Fed Extruders, 2) Gravity-Fed Extruders, and 3) 
Ram Extruders. Screw-fed extruders have screws that rotate along the horizontal axis and 
hence transport the material horizontally; they may be axial or radial screw extruders 
(Fig. 4). Axial extruders, which have a die plate that is positioned axially, consist of a 
feeding zone, a compression zone, and an extrusion zone. The product temperature is 
controlled during extrusion by jacketed barrels. In radial extruders, the transport zone is 
short, and the material is extruded radially through screens mounted around the 
horizontal axis of the screws. Gravity-fed extruders include the rotary cylinder and rotary 
gear extruders, which differ primarily in the design of the two counter-rotating cylinders 
(Fig. 5). In the rotary-cylinder extruder, one of the two counter-rotating cylinders is 
hollow and perforated, whereas the other cylinder is solid and acts as a pressure roller. In 
the so-called rotary-gear extruder, there are two hollow counter-rotating gear cylinders 
with counter bored holes. In ram extruders, a piston displaces and forces the material 
through a die at the end (Fig. 6). Ram extruders are preferred during formulation 
development because they are designed to allow for measurement of the rheological 
properties of formulations. [9, 10, 11]  
 
 
 
 
 
 
 
 
 
 
Fig. 4 Schematic representation of Screw Fed Extruders. (A) Axial Extruder 
and (B) Radial Extruder.  
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The extrusion/spheronization process was first introduced to the pharmaceutical 
industry in 1964 with the invention of the marumerizer. [13] Since then, significant 
improvements have been made to the machine, and currently well-designed marumerizers 
of different sizes are commercially available. A marumerizer or spheronizer consists of a 
static cylinder or stator and a rotating friction plate at the base. The stator can be jacketed 
for temperature control. The friction plate, which has a grooved surface, is the most 
critical part of the equipment that initiates the spheronization process. A typical friction 
plate has a crosshatch pattern, where the grooves intersect at a 90° angle, as shown in 
(Fig. 7). The groove width is selected based on the desired pellet diameter. Usually, 
groove diameters 1.5–2 times the target pellet diameter are used. The diameter of the 
friction plate is approximately 20 cm for laboratory scale equipment or up to 1.0m for 
production-scale units. The rotational speed of the friction plate is variable and ranges 
from 100 to 2000 rpm, depending on the diameter of the unit. A new variation of 
spheronizers that was introduced into the market is the so-called air-assisted spheronizers. 
Basically, they are similar to the standard spheronizers except that they are designed to 
permit a conditioned air stream to pass from beneath the rotating disk through the gap or 
slit between the cylindrical wall and the rotating friction plate into the product bed. The 
addition of such a feature presumably improves pellet turnover and brings about a spiral 
rope-like motion that facilitates spheronization. Axial-type extruders tend to produce 
extrudates with slightly higher densities. Twin-screw extruders have better material 
transport characteristics and higher capacity or throughput than do single screw extruders. 
Radial-type extruders have higher throughput but produce less dense extrudates than 
those obtained from axial-type extruders. The product temperature in radial extruders 
increases very little during the extrusion process, probably because of a shorter 
compression zone and shorter die opening depth. Absence of heat build-up during 
extrusion leads not only to well-controlled spheronization process but also allows for the 
processing of thermo labile drug substances. Although the extrusion step is a continuous 
process with a very high throughput, the subsequent steps (spheronization, drying, and 
sizing) are batch processes, and thus are rate limiting. As a result, the overall extrusion–
spheronization process is a batch rather than a continuous process.  
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Fig. 5 Schematic representation of Gravity Fed Extruder. (A) Rotary 
Cylinder Extruder and (B) Rotary Gear Extruder. 
Semi continuous process can be implemented by having an extruder feed, 
alternatively, into two spheronizers. As one of the spheronizers is spheronizing the 
extrudates, the other discharges the formed pellets and is recharged with fresh extrudates. 
The process is then repeated as the roles of the spheronizers are reversed alternately. In a 
batch process, a defined quantity of extrudate is fed into the spheronizer from the top, and 
the spheronized particles are discharged by centrifugal force via a discharge chute located 
at the base of the stator or vertical wall of the cylinder. The extrudates are spheronized by 
interparticle collisions and particle-to-wall frictional forces. The various stages of the 
spheronization process are shown in (Fig. 8). The spheronizing time is usually 2–15 min, 
depending on the formulation characteristics. Processing time remains constant, provided 
the composition of the extrudate, including the water content, and is kept constant. 
Because relatively large amounts of water or solvent are incorporated into the 
formulation, the final pellets contain significant quantities of residual moisture or solvent 
and are oven-dried or dried in a fluid-bed dryer before further processing. A sizing step 
might be necessary to separate the fractions if the particle size distribution is wider than 
intended. In general, the pellets are spherical and have a narrow particle size distribution. 
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Fig. 6 Schematic representation of Ram Extruder. 
The most critical process parameters in the spheronization step that influence the 
yield and quality are the design of the grooves and rotational speed of the friction plate 
and the residence time in the spheronizer. In an extrusion–spheronization process, 
formulation components such as fillers, lubricants, and pH modifiers play a critical role 
in producing pellets with the desired attributes. The granulated mass must be plastic and 
sufficiently cohesive and self-lubricating during extrusion. During the spheronization 
step, it is essential that the extrudates break at appropriate length and have sufficient 
surface moisture to enhance formation of uniform spherical pellets. The degree of liquid 
saturation of the granulation is another critical factor that needs to be optimized. 
Granulations containing low moisture content may generate extrudates that produce large 
quantities of fines during the spheronization step. If the moisture level is too high, the 
extrudates may adhere to each other and form bundles of strands that cannot be processed 
further. Therefore, the extrudates must have sufficient mechanical strength to form 
strands during the extrusion but must also be easily broken into uniform rods during 
spheronization to provide pellets with a narrow particle size distribution.   
 
 
 
 
 
 
 
 
Fig. 7 Schematic representation of a spheronizer friction plate with a cross-
hatch pattern 
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Excipients play a more significant role during extrusion–spheronization than 
during with any other pelletization process. They facilitate extrusion and determine the 
sphericity of the wet pellets; they also impart strength and integrity to the pellets.  
In contrast to layering processes, extrusion– spheronization can be used to 
manufacture pellets with sustained-release characteristics without the application of 
functional membranes to control release.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 8 Shape transitions during a spheronization process 
Because extrusion–spheronization is a very complex manufacturing process that 
depends on a number of formulations and processing factors (Table 1), it has been 
studied extensively. Some of these studies used multifactorial statistical designs to 
determine the significance of the various factors. Despite the extensive work that had 
been done, additional research is still ongoing as demonstrated by the number of 
publications in various scientific journals. 
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1.4 SPHERICAL AGGLOMERATION 
Spherical agglomeration, or balling, is a pelletization process in which powders, 
on addition of an appropriate quantity of liquid or when subjected to high temperatures, 
are converted to spherical particles by a continuous rolling or tumbling action. Spherical 
agglomeration can be divided into two categories Liquid Induced and Melt Induced 
agglomerations. Over the years, spherical agglomeration has been carried out in 
horizontal drum pelletizers, inclined dish pelletizers, and tumbling blenders; more recent 
technologies use rotary fluid-bed granulators and high-shear mixers.  
During liquid-induced agglomeration, liquid is added to the powder before or 
during the agitation step. As powders come in contact with a liquid phase, they form 
agglomerates or nuclei, which initially are bound together by liquid bridges. These are 
subsequently replaced by solid bridges, which are derived from the hardening binder or 
any other dissolved material within the liquid phase. The nuclei formed collide with other 
adjacent nuclei and coalesce to form larger nuclei or pellets. The coalescence process 
continues until a condition arises in which bonding forces are overcome by breaking 
forces. At this point, coalescence is replaced by layering, whereby small particles adhere 
on much larger particles and increase the size of the latter until pelletization is completed. 
[30, 31]  
If the surface moisture is not optimum, some particles may undergo nucleation 
and coalescence at different rates and form different sizes of nuclei admixed with the 
larger pellets. As a result, spherical agglomeration tends to produce pellets with a wide 
particle size distribution. The rate and extent of agglomerate formation depend, in part, 
on formulation variables such as particle size and solubility of the powder, the degree of 
liquid saturation, and the viscosity of the liquid phase. 
 Melt-induced agglomeration processes are similar to liquid-induced processes 
except that the binding material is a melt. Therefore, the pellets are formed with the help 
of congealed material without having to go through the formation of solvent-based liquid 
bridges. 
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1.5 SPRAY DRYING AND SPRAY CONGEALING 
Spray drying and spray congealing, known as globulation processes, involve 
atomization of hot melts, solutions, or suspensions to generate spherical particles or 
pellets. The droplet size in both processes is kept small to maximize the rate of 
evaporation or congealing, and consequently the particle size of the pellets produced is 
usually very small. During spray drying, drug entities in solution or suspension are 
sprayed, with or without excipients, into a hot air stream to generate dry and highly 
spherical particles. As the atomized droplets come in contact with hot air, evaporation of 
the application medium is initiated. This drying process continues through a series of 
stages whereby the viscosity of the droplets constantly increases until finally almost the 
entire application medium is driven off and solid particles are formed. Generally, spray-
dried pellets tend to be porous.  
During spray congealing, a drug substance is allowed to melt, disperse, or 
dissolve in hot melts of waxes, fatty acids, etc., and sprayed into an air chamber, where 
the temperature is below the melting temperatures of the formulation components, to 
provide spherical congealed pellets under appropriate processing conditions. A critical 
requirement in a spray congealing process is that the formulation components have well-
defined, sharp melting points or narrow melting zones. Because the process does not 
involve evaporation of solvents, the pellets produced are dense and non-porous.  
1.6 CRYOPELLETIZATION 
Cryopelletization is a process whereby droplets of a liquid formulation are 
converted into solid spherical particles or pellets by using liquid nitrogen as the fixing 
medium. The technology, which was initially developed for lyophilization of viscous 
bacterial suspensions, can be used to produce drug-loaded pellets in liquid nitrogen at 
160°C. The procedure permits instantaneous and uniform freezing of the processed 
material owing to the rapid heat transfer that occurs between the droplets and liquid 
nitrogen. The pellets are dried in conventional freeze dryers. The small size of the 
droplets and thus the large surface area facilitate the drying process. The amount of liquid 
nitrogen required for manufacturing a given quantity depends on the solids content and 
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temperature of the solution or suspension being processed. It is usually between 3 and 5 
kg per kilogram of finished pellets. 
 The most critical step in cryopelletization is droplet formation, which is 
influenced not only by formulations-related variables such as viscosity, surface tension, 
and solids content but also by equipment design and the corresponding processing 
variables. The diameter and design of the shearing edge of the holes on the container 
plates are critical. Solutions or suspensions suitable for cryopelletization have high solids 
content and low viscosities. Another important property is the surface tension of the 
liquid formulation, which partly determines the pellet size. The addition of a surfactant to 
the formulation reduces the surface tension and results in smaller particle size. Pellet size 
also depends on the properties of the drug substance.  
1.7 MELT SPHERONIZATION 
Melt spheronization is a process whereby a drug substance and excipients are 
converted into a molten or semi molten state and subsequently shaped using appropriate 
equipment to provide solid spheres or pellets. The process requires several pieces of 
equipment such as blenders, extruders, cutters (known as pelletizers in the plastics 
industry), and spheronizers. The drug substance is first blended with the appropriate 
pharmaceutical excipients, such as polymers and waxes, and extruded at a predetermined 
temperature. The extrusion temperature must be high enough to melt at least one or more 
of the formulation components. The extrudate is cut into uniform cylindrical segments 
with a cutter. The segments are spheronized in a jacketed spheronizer to generate 
uniformly sized pellets. The spheronization temperature needs to be high to partially 
soften the extrudate and facilitate deformation and eventual spheronization. [61] 
Depending on the characteristics of the formulation ingredients, pellets that exhibit 
immediate- or sustained release characteristics can be manufactured in a single step. The 
pellets produced are unique in that they are monosize, a property unmatched by any other 
pelletization technique. However, the process is still in the development stage, and 
additional work is needed before the process becomes a viable pelletization technique (15). 
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2.0 OSTEOARTHRITIS 
Osteoarthritis (OA) is a common, slowly progressive disorder affecting primarily 
the weight-bearing diarthrodial joints of the peripheral and axial skeleton. It is 
characterized by progressive deterioration and loss of articular cartilage resulting in 
osteophyte formation, pain, limitation of motion, deformity, and progressive disability. 
Inflammation may or may not be present in the affected joints. 
2.1 NONPHARMACOLOGIC THERAPY 
• The first step is to educate the patient about the extent of the disease, prognosis, 
and management approach. Dietary counseling for overweight OA patients is 
warranted. 
• Physical therapy with heat or cold treatments and an exercise programs helps to 
maintain and restore joint range of motion and reduce pain and muscle spasms. 
Exercise programs using isometric techniques are designed to strengthen muscles, 
improve joint function and motion, and decrease disability, pain, and the need for 
analgesic use. 
• Assistive and orthotic devices such as canes, walkers, braces, heel cups, and 
insoles can be used during exercise or daily activities. 
• Surgical procedures (e.g., osteotomy, joint debridement, osteophyte removal, 
partial or total arthroplasty, joint fusion) are indicated for patients with severe 
pain unresponsive to conservative therapy or pain that causes substantial 
functional disability and interference with lifestyle. 
2.2 PHARMACOLOGIC THERAPY 
2.2.1 General Approach 
• Drug therapy in OA is targeted at relief of pain. Because OA often occurs in older 
individuals who have other medical conditions, a conservative approach to drug 
treatment is warranted. 
• An individualized approach to treatment is necessary. For mild or moderate pain, 
topical analgesics or acetaminophen can be used. If these measures fail or if there 
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is inflammation, nonsteroidal anti-inflammatory drugs (NSAIDs) may be useful. 
Appropriate nondrug therapies should be continued when drug therapy is 
initiated. 
2.2.2 Nonsteroidal Anti-Inflammatory Drugs 
• NSAIDs at prescription strength are often prescribed for OA patients after 
treatment with acetaminophen proves ineffective, or for patients with 
inflammatory OA. Analgesic effects begin within 1 to 2 hours, whereas anti-
inflammatory benefits may require 2 to 3 weeks of continuous therapy. 
• All NSAIDs have similar efficacy in reducing pain and inflammation in OA 
(Table 1), although individual patient response differs among NSAIDs. 
• Selection of an NSAID depends on prescriber experience, medication cost, patient 
preference, toxicities, and adherence issues. An individual patient should be given 
a trial of one drug that is adequate in time (2 to 3 weeks) and dose. If the first 
NSAID fails, another agent in the same or another chemical class can be tried; 
this process may be repeated until an effective drug is found. Combining two 
NSAIDs increases adverse effects without providing additional benefit. 
• COX-2 selective inhibitors (e.g., celecoxib, valdecoxib) demonstrate analgesic 
benefits that are similar to traditional nonselective NSAIDs. Although COX-2 
selective inhibition was designed to reduce NSAID-induced gastropathy (e.g., 
ulcers, bleeding, perforation), concerns about adverse cardiovascular events (e.g., 
myocardial infarction, stroke) have led authorities to recommend their use only in 
selected patients who are at high risk for NSAID-related gastrointestinal effects 
and low risk for cardiovascular toxicity. 
• Gastrointestinal complaints are the most common adverse effects of NSAIDs. 
Minor complaints such as nausea, dyspepsia, anorexia, abdominal pain, 
flatulence, and diarrhea occur in 10% to 60% of patients. NSAIDs should be 
taken with food or milk; except for enteric-coated products (milk or antacids may 
destroy the enteric coating and cause increased GI symptoms in some patients). 
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• All NSAIDs have the potential to cause gastric and duodenal ulcers and bleeding 
through direct (topical) or indirect (systemic) mechanisms. Risk factors for 
NSAID-associated ulcers and ulcer complications (perforation, gastric outlet 
obstruction, GI bleeding) include age more than 65 years, comorbid medical 
conditions (e.g., cardiovascular disease), concomitant corticosteroid or 
anticoagulant therapy, and history of peptic ulcer disease or upper GI bleeding.  
• For OA patients who need an NSAID but are at high risk for GI complications, 
the ACR recommendations include either a COX-2 selective inhibitor or a 
nonselective NSAID in combination with either a proton pump inhibitor or 
misoprostol. 
NSAIDs may also cause renal complications, hepatitis, hypersensitivity reactions, 
rash, and central nervous system complaints of drowsiness, dizziness, headaches, 
depression, confusion, and tinnitus. All nonselective NSAIDs inhibit COX-1-
dependent thromboxane Production in platelets, thereby increasing bleeding risk. 
NSAIDs should be avoided in late pregnancy because of the risk of premature 
closure of the ductus arteriosus. 
The most potentially serious drug interactions include the concomitant use of 
NSAIDs with lithium, warfarin, oral hypoglycemics, high-dose methotrexate, 
antihypertensive, angiotensin-converting enzyme (ACE) inhibitors, I² blockers, 
and diuretics. 
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TABLE 1: Medications Commonly Used in the Treatment of Osteoarthritis 
MEDICATION DOSAGE AND FREQUENCY 
MAXIMUM  
DOSAGE 
(MG/DAY) 
Oral analgesics 
Acetaminophen 325-650 mg every 4-6 h or 1 g 3-4 times/day 4000 
Tramadol 50-100 mg every 4-6 h 400 
Topical analgesics 
Capsaicin 0.025% or 0.075% Apply to affected joint 3-4 times/day - 
Nutritional supplements 
Glucosamine sulfate 500 mg 3 times/day or 1500 mg once daily 1500 
Nonsteroidal anti-inflammatory drugs (NSAIDs) 
Carboxylic acids 
Acetylated salicylates 
Aspirin, plain, buffered, or 
enteric-coated 325-650 mg every 4-6 h for pain. 3600
a
 
Nonacetylated salicylates 
Salsalate 500-1000 mg 2-3 times/day 3000a 
Diflunisal 500- 1000 mg 2 times/day 1500 
Choline salicylateb 500-1000 mg 2-3 times/day 3000a 
Choline magnesium salicylate 500-1000 mg 2-3 times/day 3000a 
Acetic acids 
Etodolac 800-1200 mg/day in divided doses 1200 
Diclofenac 100-150 mg/day in divided doses 200 
Indomethacin 25 mg 2-3 times/day; 75 mg SR once daily 200; 150 
Ketorolacc 10 mg every 4-6 h 40 
Nabumetoned 500-1000 mg 1-2 times/day 2000 
Propionic acids 
Fenoprofen 300-600 mg 3-4 times/day 3200 
Flurbiprofen 200-300 mg/day in 2-4 divided doses 300 
Ibuprofen 1200-3200 mg/day in 3-4 divided doses 3200 
Ketoprofen 150-300 mg/day in 3-4 divided doses 300 
Naproxen 250-500 mg twice a day 1500 
Naproxen sodium 275-550 mg twice a day 1375 
Oxaprozin 600-1200 mg daily 1800 
Fenamates 
Meclofenamate 200-400 mg/day in 3-4 divided doses 400 
Mefenamic acide 250 mg every 6 h 1000 
Oxicams 
Piroxicam 10-20 mg daily 20 
Meloxicam 7.5 mg daily 15 
Coxibs 
Celecoxib 100 mg twice daily or 200 mg daily 200  
Valdecoxib 10 mg daily 10 
aMonitor serum salicylate levels over 3-3.6 g/day. bOnly available as a liquid; 870 mg salicylate/5 mL.Not approved for treatment 
of OA for more than 5 days.dNonorganic acid but metabolite is an acetic acid.eNot approved for treatment of OA. 
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3.0 RHEUMATOID ARTHRITIS 
Rheumatoid arthritis (RA) is a chronic and usually progressive inflammatory 
disorder of unknown etiology characterized by polyarticular symmetric joint involvement 
and systemic manifestations. 
3.1 DESIRED OUTCOME 
• The ultimate goal of RA treatment is to induce a complete remission, although 
this is seldom achieved. 
• The primary objectives are to reduce joint swelling, stiffness, and pain; preserve 
range of motion and joint function; improve quality of life; prevent systemic 
complications; and slow destructive joint changes. 
3.2 NONPHARMACOLOGIC THERAPY 
• Adequate rest, weight reduction if obese, occupational therapy, physical therapy, 
and use of assistive devices may improve symptoms and help maintain joint 
function. 
• Patients with severe disease may benefit from surgical procedures such as 
tenosynovectomy, tendon repair, and joint replacements. 
3.3 PHARMACOLOGIC THERAPY 
3.3.1 General Approach 
• A disease-modifying antirheumatic drug (DMARD) should generally be started 
within the first 3 months of symptom onset. DMARDs should be used in all 
patients except those with limited disease or those with class IV disease in whom 
little reversibility is expected. Early use of DMARDs results in a more favorable 
outcome and can reduce mortality. 
• First-line DMARDs include methotrexate, hydroxychloroquine, sulfasalazine, and 
leflunomide. The order of agent selection is not clearly defined. 
Hydroxychloroquine or sulfasalazine may be used initially in mild disease, 
butmethotrexate is often chosen initially in more severe cases because of long-
term data suggesting superior outcomes than other DMARDs and lower cost than 
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biologic agents. Leflunomide appears to have long-term efficacy similar to 
methotrexate. 
• Biologic agents with disease-modifying activity include the anti-TNF agents 
(etanercept, infliximab, adalimumab) and the interleukin-1 receptor antagonist 
anakinra. Biologic agents are effective for patients who fail treatment with other 
DMARDs. 
• DMARDs that are less frequently used include azathioprine, penicillamine, gold 
salts (including auranofin), minocycline, cyclosporine, and cyclophosphamide. 
These agents have either less efficacy or high toxicity, or both. 
• Combination therapy with two or more DMARDs may be effective when single-
DMARD treatment is unsuccessful. Combinations that are particularly effective 
include (1) methotrexate plus cyclosporine, and (2) methotrexate plus 
sulfasalazine and hydroxychloroquine. 
• Nonsteroidal anti-inflammatory drugs (NSAIDs) and/or corticosteroids may be 
used for symptomatic relief if needed. They provide relatively rapid improvement 
compared with DMARDs, which may take weeks to months before benefit is 
seen. However, NSAIDs have no impact on disease progression, and 
corticosteroids have the potential for long-term complications. 
• See Table 2 for usual dosages and monitoring parameters for DMARDs and 
NSAIDs used in rheumatoid arthritis. 
3.3.2 Nonsteroidal Anti-Inflammatory Drugs (NSAIDS) 
NSAIDs act primarily by inhibiting prostaglandin synthesis, which is only a small 
portion of the inflammatory cascade. They possess both analgesic and anti-inflammatory 
properties and reduce stiffness but do not slow disease progression or prevent bony 
erosions or joint deformity. They should seldom be used as monotherapy for rheumatoid 
arthritis. 
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TABLE 2: Clinical Monitoring Of Drug Therapy In Rheumatoid Arthritis 
  DRUG TOXICITIES 
REQUIRING 
MONITORING 
SYMPTOMS TO INQUIRE 
ABOUT A 
NSAIDs and 
salicylates 
Gl ulceration and 
bleeding, renal damage 
Blood in stool, black stool, 
dyspepsia, 
nausea/vomiting, weakness  
Corticosteroids Hypertension, 
hyperglycemia, 
osteoporosisb 
Blood pressure if available, 
polyuria, polydipsia, 
edema, shortness of breath, 
visual changes, weight 
gain, headaches, broken 
bones or bone pain 
Azathioprine Myelosuppression, 
hepatotoxicity, 
lymphoproliferative 
disorders 
Symptoms of 
myelosuppression (extreme 
fatigue, easy bleeding or 
bruising, infection), 
jaundice 
Gold (intramuscular 
or oral) 
Myelosuppression, 
proteinuria, rash, 
stomatitis 
Symptoms of 
myelosuppression, edema, 
rash, oral ulcers, diarrhea 
Hydroxychloroquine Macular damage, rash, 
diarrhea 
Visual changes including a 
decrease in night  
Methotrexate Myelosuppression, 
hepatic fibrosis, 
cirrhosis, pulmonary 
infiltrates or fibrosis, 
stomatitis, rash 
Symptoms of 
myelosuppression, 
shortness of breath, 
nausea/vomiting lymph 
node swelling, coughing 
Leflunomide Hepatitis, Gl distress, 
alopecia 
Nausea/vomiting, gastritis, 
diarrhea, hair loss, jaundice 
Penicillamine Myelosuppression, 
proteinuria, stomatitis, 
rash, dysgeusia 
Symptoms of 
myelosuppression, edema, 
rash, diarrhea, altered taste  
Sulfasalazine Myelosuppression, rash Symptoms of 
myelosuppression, 
photosensitivity, rash, 
nausea/vomiting 
Etanercept, 
adalimumab, 
anakinra 
Local injection-site 
reactions, infection 
Symptoms of infection 
Infliximab Immune reactions, 
infection 
Postinfusion reactions, 
symptoms of infection 
a
 Altered immune function increases infection, which should be considered, particularly in 
patients taking azathioprine, methotrexate, corticosteroids, or other drugs that may produce 
myelosuppression. b Osteoporosis is not likely to manifest early in treatment, but all patients 
should be taking appropriate steps to prevent bone loss. 
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• Cyclooxygenase-2 (COX-2) selective NSAIDs have a better gastrointestinal (GI) 
safety profile and similar efficacy as conventional NSAIDs. 
TABLE 3: Dosage Regimens for Nonsteroidal Anti-Inflammatory Drugs 
  
Recommended Total Daily Anti-inflammatory Dosage 
  
Drug Adult Children Dosing Schedule 
Aspirin 2.6-5.2 g 60-100 mg/kg 4 times daily 
Celecoxib 200-400 mg - Once or twice daily 
Diclofenac 150-200 mg - 3-4 times daily 
Extended release: 
twice daily 
Diflunisal 0.5-1.5 g - Twice daily 
Etodolac 0.2-1.2 g 
(max, 20 
mg/kg) 
- 3-4 times daily 
Fenoprofen 0.9-3.0 g - 4 times daily 
Flurbiprofen 200-300 mg - 2-4 times daily 
Ibuprofen 1.2-3.2 g 20-40 mg/kg 3-4 times daily 
Indomethacin 50-200 mg 2-4 mg/kg 
(max, 200 mg) 
2-4 times daily 
Extended release: once 
daily 
Ketoprofen 150-300 mg - 3-4 times daily 
Extended release: once 
daily 
Meclofenamate 200-400 mg - 3-4 times daily 
Meloxicam 7.5-15 mg - Once daily 
Nabumetone 1-2 g - Once or twice daily 
Naproxen 0.5-1.0 g 10 mg/kg twice daily Extended 
release: once daily 
Naproxen sodium 0.55-1.1 g - Twice daily 
Nonacetylated 
salicylates 
1.2-4.8 g   2-6 times daily 
Oxaprozin 0.6-1.8 g 
(max, 26 
mg/kg) 
  1-3 times daily 
Piroxicam 10-20 mg - Once daily 
Sulindac 300-400 mg - Twice daily 
Tolmetin 0.6-1.8 g 15-30 mg/kg 3-4 times daily 
Valdecoxib 10 mg - Once daily 
 
 
Common NSAID dosage regimens are shown in Table 3.  
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2. LITERATURE REVIEW 
Fu Jijun et al, (2011)14 developed matrix extended release pellets of Diclofenac 
potassium using low amount of release modifying agents and compared its performance 
in vivo with coated pellets and matrix tablets. Coated pellets were prepared by extrusion 
spheronization, followed by double layer coating using different polymers separately. Bio 
availability study of different coated pellets revealed drug concentration in plasma of 
beagle dogs was too low to be detected. 
J.C.O. Villanova et al, (2011)59 evaluated the physicochemical and flow properties of 
new polymeric excipients of ethyl acrylate, methyl methacrylate and butyl methacrylate, 
synthesized by suspension polymerization using cellulose nanowhiskers as co-stabilizer, 
to be used as direct compression for modified release. Particle size analysis of the beads 
with cellulose nanowhiskers (CNWB) indicated that the presence of the nanowhiskers led 
to a reduction of particle size a. In vitro test showed that the nanowhiskers and beads 
produced are nontoxic. The beads are used to produce tablets by direct compression 
contained propranolol hydrochloride as model drug.  
Claire Gendre et al, (2011)6 Performed in-line Near Infrared (NIR) measurements inside 
a pan coater to monitor a coating operation in real-time, by predicting the increases in 
mass of coating materials and coating thickness. A polymer combination of ethyl 
cellulose/poly (vinyl-alcohol)–poly (ethylene-glycol) graft copolymer was used as 
functional aqueous coating. Coated tablets were sampled at regular interval during the 
coating operation, then subjected to both simple and fast weighing (n = 50) or accurate 
and non-destructive Terahertz Pulsed Imaging (TPI) measurements (n = 3). 
Sonali R.Naikwade et al, (2009)52 developed enteric coated pellets of piroxicam in order 
to avoid local gastrointestinal irritation which is major side effect of non steroidal anti 
inflammatory drugs. Pellets were made by extrusion–spheronization process .Three 
polymers namely Eudragit L100, cellulose acetate phthalate, and hydroxyl propyl methyl 
cellulose phthalate were used. Enteric pellets prepared using Eudragit L 100 gave 
promising results for matrix pellets. 
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Ekarat Jantratid et al,(2009)11 developed  Invitro dissolution of MR Diclofenac sodium 
pellets containing 100mg active ingredient was evaluated under simulated pre- and 
postprandial condition using USP Apparatus 3 (reciprocating cylinder, Bio-Dis) and 4 
(flow-through cell) and results compared with compendial methods using USP Apparatus 
1 (basket) and 2 (paddle).  The in vitro results were compared with the in vivo data by 
means of Level A in vitro–in vivo correlation (IVIVC) and Weibull distribution analysis. 
The biorelevant dissolution tests predicted correctly that the release (and hence 
absorption) of Diclofenac sodium would be slower in the fed state than in the fasted state. 
Youness Karrout et al, (2009)62 prepared and characterized novel types of polymer 
coated pellets allowing for the site-specific delivery of drugs to the colon. 5-
Aminosalicylic acid (5-ASA)-loaded beads were prepared by extrusion–spheronization 
and coated with different Nutriose: ethylcellulose blends. In vitro drug release from these 
systems was measured under exposure to fresh fecal samples from inflammatory bowel 
disease patients under anaerobic conditions.  
Simon Ensslin et al, (2009)50 clarified the influences of three coating parameters on the 
drug release from chlorpheniramine maleate pellets coated with blends of poly (vinyl 
acetate) (PVAc) and poly (vinyl alcohol)-poly (ethylene glycol) (PVA-PEG) polymer. 
The Solubilisation inside pellets was monitored by EPR spectroscopy. A mathematical 
model was developed and it offers possibility to achieve a defined drug release. 
Tamara Iosio et al, (2008)56 formulated pellets by extrusion /spheronization with two 
cohesive layers. One of them contains a self emulsifying system for vincopectine, a 
poorly water soluble model drug. Two layers were prepared: an inert layer of micro 
crystalline cellulose, lactose and water and second one wetted with self-emulsifying 
system. Pellets type II revealed improved drug solubility and in vivo bio availability. 
Ahmed abdalla et al, (2008)1 developed a new pellet based self-emulsifying (SE) drug 
delivery system for the oral delivery of poorly soluble drugs. Furthermore, investigated 
the influence of physiological dilution media and enzymatic digestion on the 
solublization capacity of the formulation for the model drug Progesterone. Lipid mixtures 
composed of Solutol® HS 15 and medium chain glycerides were optimized with respect 
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to their self-emulsifying properties. The liquid SE lipid was mixed with microcrystalline 
cellulose and transformed into pellets by extrusion/spheronization. The pellets were 
characterized for size, shape, surface characteristics and friability. Pellets with good 
properties (size, shape and friability) have been produced through the incorporation of a 
selected SE mixture into MCC. 
Pornsak Sriamornsak et al, (2007)18 investigated the possibility of producing alginate –
based pellets by extrusion/spheronization .Two types of sodium alginate (30%) were 
evaluated in combination with theophylline (20%), micro crystalline cellulose (50%) and 
different granulation fluids. Most of pellet formulations released about 75-85%drug 
within 60 min and showed good fit to both Higuchi and Korsmeyer-Peppas equations.  
Mauro  Serratoni et al, (2007)27 prepared pellets by extrusion /spheronization 
containing two model drugs (methyl and propyl parabens) of low water solubility. One 
type of pellets contained  drugs mixed with lactose and micro crystalline cellulose and 
other types of pellets contained the model drugs dissolved in self -emulsifying 
system(4,8%)consisting of equal parts of mono glycerides and polysorbate 80 and MCC. 
The application of sub coating of hydroxypropyl methyl cellulose was able to reduce the 
release rate of methyl parabens self emulsifying ethyl cellulose coated pellets. 
Caroline D´esir´ee Kablitz et al, (2006)51 developed a highly efficient dry coating 
process to obtain an enteric film avoiding completely the use of organic solvents and 
water. Using hydroxypropyl methylcellulose acetate succinate (HPMCAS) an enteric coat 
should be obtained without adding talc as antitacking agent because of problems arising 
from microbiological contamination. Further on, a method was developed preparing 
isolated films in order to determine the glass transition temperature (Tg) and the required 
process temperature. The dry coating process has been demonstrated to be a serious 
alternative to conventional solvent or water based coating processes. 
Ross A. Kennedy et al, (2006)46 Formulated Calcium alginate gel-coated pellets by 
forming an insoluble gel coat on extruded–spheronized pellets by interfacial 
complication. Alginate with high guluronic acid content gave the slowest release. The 
faster drug release in acidic media and 0.1M NaCl compared to water is probably due to 
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reduced calcium cross-linking in the gel. These results suggest that the pellet size, 
alginate type and concentration and dissolution medium influenced the swelling and drug 
release behavior of calcium alginate gel-coated pellets. 
Els Mehuys et al, (2005)12 developed an alternative technique for enteric coating 
consisting of the hot-melt extrusion of coating polymers. An enteric coating polymer 
(PVAP or HPMC AS), premixed with a plasticizer, was extruded into hollow cylinders. 
The hollow pipes were filled with a model drug and both open ends of the cylinders were 
closed, yielding hot-melt extruded enteric capsules.  The enteric capsules showed 
excellent gastro-resistance, since no drug release was observed after 2 h 0.1N HCl.  It can 
be concluded that hot-melt extruded capsules seem suitable as an alternative for enteric 
coating 
Helton Santos et al, (2005)19 investigated about compaction and compression of xanthan 
gum pellets and evaluated its drug release from tablets made of pellets. Formulation 
includes xanthan gum, at 16 %( w/w), Diclofenac sodium or ibuprofen, at 10 %( w/w) 
.An amount of 500mgof pellets fraction 1000-1400 µm were compacted in single punch 
press at maximum punch pressure of 125MPa using flat-faced punches. Tablets made of 
pellets comprising ibuprofen released model drug in bimodal fashion and release 
behavior was characterized as case II transport mechanism (release exponent of0.93).   
Caroline De Brabander et al, (2004)4 tested the bio-availability of ibuprofen from hot-
melt extruded mini matrices based on ethyl cellulose and hydrophilic excipients. during 
the in vivo evaluation on oral dose of 300 mg was administered to healthy volunteers 
(n=9) in a randomized cross-over study and compared with a commercially available 
sustained release product(Ibu-slow).The plasma samples were analyzed by validated 
HPLC-UV method. 
Ann Debunne et al, (2004)3 investigated the influence of formulation and compression 
parameters on the properties of tablets, containing enteric-coated pellets, and on the 
integrity of the enteric polymer of the individual pellets after compression. Tablets 
consisted of enteric-coated pellets (containing 2.5% (w/w) piroxicam in combination with 
microcrystalline cellulose and sodium carboxymethyl cellulose (using Avicel® PH 101 
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and Avicel® CL 611 in a ratio of 1–3)), cushioning waxy pellets and 10%  Kollidon® CL 
(as an external disintegrator). A dosing interval of 48 h prevented piroxicam 
accumulation following multiple dose administration. 
H.Steckel et al, (2004)54 prepared chitosan pellets using extrusion/ spheronization 
technology. Microcrystalline cellulose was used as additive in concentrations from 70 to 
0%.The powder mixtures were extruded using demineralised water and diluted acetic 
acid in different powder to liquid ratios. With DM water as granulating fluid, pellets with 
a maximum of 50 %( m/m) could be produced. 
A.Kramar et al, (2003)23 evaluated   three formulation parameters for the application of 
poly methacrylic films from aqueous dispersions in order to obtain multi particulate 
sustained release of Diclofenac sodium. The chosen independent variables, i.e., the 
concentration of plasticizer (tri ethyl citrate), methacrylate polymers ratio (Eudragit RS: 
Eudragit RL) and the quantity of coating dispersions were optimized with a three-factor 
Box-Behnken design. Different release profiles were obtained. 
Hanan F.Kakish et al,(2002)18 prepared modified –release dosage forms  of diltiazem 
HCl and Diclofenac sodium .The development work comprised two main parts :(a) 
loading the drug into ethylene vinyl acetate (EVA)polymer ,and (b)generation  of a non 
uniform concentration distribution of drug within the polymer matrix .Phase separation  
technique was successfully used to load diltiazem HCl and Diclofenac sodium into 
polymer at significant levels ,up to 81 and 76%respectively. 
B.Sreenivasa Rao et al, (2002)53 Studied the rifampicin release studies from ethyl 
cellulose coated non pareil beads. Propylene glycol and castor oil were used as 
plasticizers. The in vitro dissolution studies revealed that the release rate is inversely 
proportional to percent of coating thickness. It also depends on type of plasticizer used. 
The mechanism off drug release follows Higuchi diffusion model. 
Sally Y. Choe et al, (2001)47 validated the Pellet Gastric Emptying Test (PGET) as a 
marker of gastric emptying; a randomized, four-way crossover study was conducted with 
12 healthy subjects. The study consisted of oral co-administration of enteric coated 
caffeine (CAFF) and acetaminophen (APAP) pellets in four treatment phases: Same Size 
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(100 kcal), Fasted, Small Liquid Meal (100 kcal), and Standard Meal (847 kcal). The 
time of first appearance of measurable drug marker in plasma, initial, was taken as the 
emptying time for the markers. The results suggest that the pellet gastric emptying test 
could prove useful in monitoring changes in transit times in the fasted and fed states and 
their impact on drug. 
Karen M.O’Connor et al, (2001)21 studied physiological properties of Diclofenac salts 
prepared using eight different counter ions and including five novel salts, obtained with 
the bases 2-amino-2-methyl-1, 3-propane diol, 2-amino -2-methyl propranolol, tert-
butylamine, benzyl amine and deanol .Characterisation techniques included X-Ray 
diffraction, differential scanning calorimetry, thermo gravimetric analysis, thermo 
microscopy, karl fischer titration, FT-IR and elemental analysis. The solubility of 
Diclofenac deanol was higher than Diclofenac salts. 
T. Waaler et al, (1999)60 Formulated Enteric coated dexchlorpheniramine maleate 
(DCPA) tablets and pellets with varying coating thickness and subjected to several in 
vitro tests after irradiation by thermal neutrons in a flux of 1.1310 n cm s for 2, 4 or 15 
min. The appearance of the tablet formulation changed extensively after exposure of the 
tablets to pile radiation. The irradiation caused the film to loosen from the surface of the 
core, indicating the generation of gases during the irradiation process. Although the 
dissolution behavior of the pellet formulations changed significantly after the irradiation 
procedure, the changes were too small to be attributed exclusively to radiation damage.  
Anandrao R. Kulkarni et al, (1999)2 formulated Controlled release sodium alginate 
_Na–Alg. beads containing Diclofenac sodium by precipitation of Na–Alg in alcohol 
followed by cross linking with glutaraldehyde in acidic medium. Preparation of the beads 
was optimized by considering the percentage entrapment efficiency, swelling capacity of 
beads in water and their release data.   The beads produced at higher temperatures and 
longer times of exposure to the cross linking agent have shown the lower entrapment 
efficiency, but extended release of DS from the beads. 
M. Marvola et al, (1999)26 developed a multiple-unit, site-specific drug formulation 
allowing targeting of drug release in the colon.  Ibuprofen and furosemide were used as 
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model drugs. The former is absorbed throughout the gastrointestinal tract, the latter only 
from upper parts. Methacrylate copolymers, hydroxypropyl methylcellulose acetate 
succinate and cellulose acetate phthalate were used as enteric polymers. The main 
conclusion was that drug release can be targeted on the distal part of the small intestine 
and the colon by preparing film-coated matrix pellets in which enteric polymers 
dissolving at pH 7 have been used both as binders in the pellets and as coating material.  
C. Lustig-Gustafsson et al, (1999)25 investigated   the influence of drug solubility in the 
range 14.3–1000 g l on the formation of pellets by extrusion and spheronization by 
evaluating the performance of a series of model drugs mixed with an equal part by weight 
of microcrystalline cellulose. The optimum water level required to form the best quality 
pellets was found to decrease as a linear function of the natural logarithm of the water 
solubility of the drug. 
M.J.Fernandez-Hervas et al, (1998)13 formulated alginate beads containing Diclofenac 
hydroxyl ethylyrolidine with either Eudragit or chitosan in order to achieve enteric 
formulation   .In all cases, high entrapment efficiencies were obtained. Under conditions 
mimicking those in stomach, a small amount of drug was released. 
J.Vertommen et al, (1997)58 studied the shape and surface smoothness of pellets made in 
rotary processor by wet granulation. Optical microscopy combined with image analysis 
was used to determine three shape parameters (circularity, roundness and elongation) and 
fractal dimension, which is a characteristic for surface smoothness of pellets. This study 
reveals that pellets made in rotary processor are more variable in terms of their shepricity 
than in terms of their elongation. 
P.B.Deasy et al, (1997)7 developed two new pelletized formulations of Indomethacin and 
compared against pellets from proprietary product, Indocid-R. Extensive dissolution 
testing showed new product containing polyvinyl pyrolidone had slightly faster in –vitro 
release than commercial product. The other new product containing sodium lauryl 
sulphate had reduced release rate. 
Timm Trenktrog et al, (1996)57 Formulated pellets with human insulin as model drug 
by extrusion-spheronization process to investigate oral application of peptides. The 
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developed formulation was completed by addition of aprotonin as protease inhibitor 
sodium cholate as an intestinal absorption enhancer to enhance bio-availability of insulin. 
Further coated with shellac to protect the peptide against gastric juice .rapid and complete 
release of molecular –dispersed insulin from pellets was found in simulated intestinal 
fluid (PH 7.5). 
J.Sujja-areevath et al, (1996)55 designed an oral sustained release multiple-unit dosage 
form of Diclofenac sodium and evaluated the use of four natural hydrophilic gums as 
mini -matrix formulations enclosed in hard gelatin capsule. Carrageenan, locust bean, 
karaya and xanthan gums were used to produce mini-matrices. The amount of gum 
present play dominant role in determining drug release rate. 
M.P.Gouldson et al, (1996)16 investigated for the in-situ formation of an enteric co –
precipitate of nifidipine with hydroxypropyl methylcellulose phthalate (HP-55) in 
spherical pellets. The use of various spheronization aids such as lactose, kaolin, aerosol 
972 and 200, Bentone 27, liquid paraffin and magnesium state was studied. The final 
product containing sodium lauryl sulphate 2%as wetting agent and starch glycolate 5% as 
disintegrant processed with optimum solvent level, gave high yield of acceptable spheres. 
Klaus knop et al,(1996)22 Used aqueous dispersions of acrylic resins poly ethyl acrylate-
methyl methacrylate-tri methyl ammonio ethyl methacrylate chloride(Quaternary 
PMMA,Eudragit RS 30D) and poly ethyl acrylate-methyl methacrylate (Nuetral PMMA 
,Eudragit NE 30D) to cast free films and to coat theophylline pellets. The release of 
theophylline from pellets coated with Eudragit RS showed a great dependence on 
composition of buffer solution. The highest release rates were observed in format buffers, 
intermediate in phosphate buffers, low in citrate buffers and in buffers containing 
chloride ions. 
W.Gunder et al, (1995)17 Designed diffusion pellets (coated pellets) by adding Hydroxyl 
propyl methyl cellulose to aqueous ethyl cellulose (EC) dispersions with 20% dibutyl 
Sebacate(DBS) as plasticizer. Formulated diffusion pellets contain water-filled pores in 
release-controlling membrane after extraction of HPMC at beginning of release process. 
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Drug is released practically exclusively via distribution-diffusion mechanism. Pores also 
close in case of HMPC  content of 30-40% but not completely. 
Delphine Blanque et al, (1995)8 evaluated the influence of formulation factors such as 
drug solubility, drug content, the quantity and type of release modifying agents and type 
of filler on formation and drug release from pellets formed by extrusion /spheronization. 
The molecular weight of polyethylene glycols was shown to be main factor influencing 
median pellet size and steady state extrusion force. Important factors appeared to be drug 
solubility and choice of filler 
Sanjay R.Goskonda et al, (1994)48 developed modified-release spherical pellets using a 
radial basket-type extruder and serrated plate spheronizer. A Box-Behnken response 
surface experimental design was employed to address the effects of altering the 
concentration of Eudragit RS 30D,Avicel RC-591,Fumaric acid, and acetyl tri butyl 
citrate .Controlled release pellets were produced that met dissolution specifications 
without subsequent coating.  
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3. AIM AND OBJECTIVE 
Aim of the present research study is to develop Diclofenac sodium enteric coated 
pellets using Kollicoat MAE 100 P and Eudragit L 100 by Extrusion-Marumerisation 
technique. 
Objective Diclofenac sodium is a water insoluble non steroidal anti inflammatory 
drug used in the treatment of chronic rheumatoid arthritis and osteoarthritis. Diclofenac 
sodium was enteric coated and presented as enteric coated Diclofenac sodium pellet in a 
capsule dosage form.   
The key target of our study is to fabricate a Diclofenac pellets with uniform size 
and shape which increases the gastrointestinal transit time. In order to protect Diclofenac 
sodium release in the stomach, pellets were enteric coated and made available in the 
small intestine for release in the range of 6 – 7.5pH.  
Rationale for the selection of dosage form is to minimize large variation in gastric 
emptying / residence time, less susceptible to dose dumping, facilitate accurate delivery 
of small quantity of potent drugs, reduced drug concentration at sites other than target 
organ, and maximizes drug absorption in small intestine, reduced potential side effects 
without lowering drug bio availability. 
Rationale for the selection of enteric coating Diclofenac sodium has been reported 
with GI bleeding, ulceration and perforation can be fatal. So, Diclofenac sodium was 
enteric coated with enteric coating polymer such as Kollicoat MAE 100P , Eudragit L 
100 and minimized the release in the stomach. 
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4. PLAN AND SCOPE OF THE WORK 
Objective of the study is to produce an enteric coated pellet dosage form using 
Diclofenac sodium. It is achieved by doing preformulation, formulation, evaluation, and 
stability studies for the drug and excipients. 
A) Preformulation studies: 
1) Active pharmaceutical ingredient profile study 
2) Excipient profile study 
3) Characterization of active pharmaceutical ingredient and polymer using 
FT-IR 
4) Thermal analysis for characterizing interaction between drug and 
excipients 
5) Analysis of excipients compatibility by stability studies. 
 
B) Formulation and evaluation: 
Fabrication of core pellets 
1) Formulation of Diclofenac sodium pellets 
2) Evaluation of Diclofenac sodium pellets 
 
Enteric coating for core pellets 
3) Enteric coating for optimized pellets with different enteric polymers 
4) Evaluation of enteric coated pellets 
 
Reproducibility for optimized batch   
5) Reproducibility of core pellets and enteric coating with suitable polymer 
and its evaluations 
6) SEM Analysis for core and coated pellets 
 
C) Stability study of enteric coated pellets 
D) Comparison with marketed sample 
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A) PREFORMULATION STUDIES: 
Active pharmaceutical ingredient profile study28 
Studying of API profile is essential and foremost stage in preformulation. The 
intrinsic reactivity of the APIs in the solid state is very important, because it can be 
accentuated by the presence of water. The reactivity of the drug is made possible through 
a four-step process:  
 Molecular loosening or mobility. 
 Molecular change: this involves breaking of chemical bonds of the reactant (drugs 
and/or excipients) and formation of the new one in the product. 
 Solid solution formation. 
 Separation of product. 
Excipients profile study 
 Excipient profile study is based on the inherent properties of the excipients and 
their importance in the delivery of the active ingredients to the target site. Excipients are 
contradictory to their original statement as “inert,” but they are “enabling” substances 
which change the character of a dosage form. This may react with API and affects the 
characteristics of drug and dosage form. 
Characterization of active pharmaceutical ingredient and polymer using FT-IR29 
Fourier transform infrared spectroscopy is a powerful tool for structural 
confirmation of the active drug, allowing the generation of much information with very 
little expenditure of drug substance or time. In this case, FT-IR required to aid in 
understanding the nature of the interactions and determines whether they are relevant in 
formulation development. 
Thermal analysis for characterizing interaction between drugs and excipients30 
Drug–excipients interaction is one of the most important considerations in solid 
dosage form development and in drug discovery programs. If this study done with 
inadequacy leads to serious consequences such as formation of new impurities, 
incomplete mass balance, destruction of the dosage form, unnecessary multiplicity of 
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prototype formulations, changes in physicochemical properties and inability to obtain 
successful dosage form. 
Analysis of excipients compatibility using stability studies method 
Excipient compatibility study done to find out the unwanted results on storage for 
a period of time, by this we may avoid spurious effects on developed dosage form on 
storage.   
B) FORMULATION AND EVALUATION: 
Formulation of Diclofenac sodium core pellets 
Pellets were prepared by spheronization and marumarization method for the ease 
in preparation as well to require uniform size and shape to the pellets. 
Evaluation of Diclofenac sodium core pellets 
Angle of repose, bulk density, tapped density, Carr’s index, Hauser’s ratio, loss 
on drying water absorption ratio, friability, assay and dissolution are the parameters 
chosen to evaluate pellets. 
Enteric coating for optimized core pellets 
Enteric coating were done to the Diclofenac sodium pellets to minimize the 
release in the stomach and made available in the small intestine to reduce the unwanted 
side effects of the drug in the stomach. 
Evaluation of enteric coated pellets 
Angle of repose, bulk density, tapped density, Carr’s index, Hauser’s ratio, loss 
on drying water absorption ratio, friability, assay and In-vitro dissolution study was 
conducted for the enteric coated pellets to find the amount of Diclofenac sodium release 
in acidic pH. 
Reproducibility for enteric coated pellets with its evaluation 
Reproducibility of the optimized batch preparation was done with its respective 
core and coated pellets evaluations. These tests were done to pellets to find out its 
reproducibility on preparation and stability on administration, transportation and storage. 
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Scanning electron microscope for the core and coated pellets 
SEM analysis was done to core and coated pellets to find out appropriate size of 
the pellets and to evident the increase in size of the pellets after coating.  
C) STABILITY STUDY OF ENTERIC COATED PELLETS 
            In the development of enteric coated Diclofenac sodium pellets, the stability of 
the dosage form is evaluated; samples are stored under appropriate stressful 
environmental conditions so as to identify any circumstances that would lead to 
degradation of the dosage form. Examples of suitable stress would include increased 
temperature, elevated relative humidity, and exposure to high intensity light. Samples are 
withdrawn at definite time intervals and analyzed for the stability.  
D) COMPARISON WITH MARKETED SAMPLE 
           The optimized pellet formulation (C8) was compared with marketed pellet 
formulation to find out the similarity and differences between them.  
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5. PREFORMULATION 
 
5.1 ACTIVE PHARMACEUTICAL INGREDIENT PROFILE 
5.1.1 Diclofenac sodium10 
Therapeutic Category: Non steroidal anti-inflammatory drugs 
Structure:      
 
DICLOFENACSODIUM 
Chemical Name: Sodium 2-[(2, 6-dichlorophenyl) amino] phenyl] acetate. 
Molecular Formula: C14 H10Cl2NNaO2 
Molecular Weight: 318.1g/mol 
Description: White or slightly yellowish, slightly hygroscopic, crystalline powder. 
Appearance: White crystals 
Solubility: Sparingly soluble in water, freely soluble in methanol, soluble in ethanol 
(96%) slightly soluble in acetone. 
Melting point: About 280°C with decomposition. 
Loss on drying: Maximum 0.5%, determined on 1.0g by drying in an oven at 105°C for 
3h.  
Residue on ignition: Not more than 0.1% 
Heavy metals: Maximum 10ppm. 
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Dose: 75 to 150mg daily, in divided doses for adults. 
Storage: in an air tight container protected from light. 
Mechanism of Action: 
The exact mechanism of action is not entirely known, but it is thought that the 
primary mechanism responsible for its anti-inflammatory, antipyretic, and analgesic 
action is inhibition of prostaglandin synthesis by inhibition of cyclooxygenase (COX). It 
also appears to exhibit bacteriostatic activity by inhibiting bacterial DNA synthesis. 
Inhibition of COX also decreases prostaglandins in the epithelium of the stomach, 
making it more sensitive to corrosion by gastric acid. This is also the main side-effect of 
diclofenac.  
Pharmacokinetic profile: 
Absorption: Diclofenac is completely absorbed after their passage through the stomach. 
Distribution: 99.7% of Diclofenac is bound to serum proteins mainly to albumin 
(99.4%). Diclofenac enters the synovial fluid, where peak concentrations are measured 
2.4 hrs after the peak plasma levels have been reached.  
Half life: 1.0 – 2.0 hours 
Metabolism: Biotransformation of Diclofenac takes place by glucuronidation partly of 
the intact molecule, but mainly by glucuronidation after single and multiple 
hydroxylations. 
Excretion: 60% of the drug excreted via kidney as metabolites, less than 1.0% excreted 
unchanged in urine 
Therapeutic uses: for the treatment of rheumatoid arthritis, osteoarthritis and as 
analgesic. 
Contraindication: Peptic ulcer, known hypersensitivity reaction to the Diclofenac 
sodium. Like other non-steroidal anti-inflammatory agents, Diclofenac is contraindicated 
Chapter V                                                                                                   Preformulation 
Department of Pharmaceutics                       41       JKKMMRF College of Pharmacy 
in patients in whom attacks of asthma, urticaria or acute rhinitis have been precipitated by 
acetylsalicylic acid or other prostaglandin-synthetase inhibitors. 
Adverse drug reactions  
Gastrointestinal tract: Epigastric pain, other gastrointestinal symptoms, e.g., nausea, 
vomiting, diarrhea, abdominal cramps, dyspepsia, flatulence, anorexia, gastrointestinal 
bleeding, haematemesis, melaena, peptic ulcer with or without bleeding or perforation, 
bloody diarrhea, lower gut disorders leg. Non specific hemorrhagic colitis and 
exacerbation of ulcerative colitis or Crohn's disease); aphthous stomatitis, glossitis, 
oesophageal lesions, constipation. 
Central (and peripheral) nervous system: Headache, dizziness or vertigo. 
Skin: Skin rash, urticaria. Kidney: Isolated cases: Acute renal failure, haematuria, 
proteinuria, interstitial nephritis, nephrotic syndrome, papillary necrosis. 
Liver: Elevated serum aminotransferases (SGOT, SGPT). 
Hypersensitivity reactions: Hypersensitivity reactions, e.g. asthma, systemic 
anaphylactic / anaphylactoid reactions (including hypotension). 
Drug interaction:  
Lithium / digoxin: Diclofenac may raise plasma concentrations of lithium or digoxin 
when given together with preparations containing these substances. 
Diuretics: Some nonsteroidal anti-inflammatory agents can inhibit the effect of diuretics. 
Concomitant treatment with potassium-sparing diuretics may raise serum potassium 
levels which should therefore be monitored. 
NSAIDs: Concomitant administration of various systemic nonsteroidal anti-
inflammatory drugs may increase the frequency of adverse effects. 
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Anticoagulants: Although no evidence appear to suggest that Diclofenac affects the 
action of anticoagulants, an increased risk of hemorrhage in patients receiving Diclofenac 
and anticoagulants concomitantly has been reported in isolated cases. It is therefore 
advisable to monitor such patients carefully. 
Like other non steroidal ant rheumatic agents, Diclofenac may temporarily inhibit platelet 
aggregation when given in high doses (200 mg). 
Ant diabetic agents: It has been shown that Diclofenac can be given concomitantly with 
oral ant diabetic agents without influencing their clinical effect. 
However, isolated cases have been reported of hypoglycemic and hyperglycemic 
reactions, necessitating an adjustment in the dosage of anti diabetic drugs treatment with 
diclofenac. 
Methotrexate: Caution is called for if nonsteroidal anti-inflammatory agents are 
administered < 24 hrs before or after treatment with methotrexate, since methotrexate 
levels in the blood may rise and the toxicity of this substance is increased. 
Cyclosporine: The effect of non-steroidal anti-inflammatory drugs on renal 
prostaglandins may increase the nephrotoxicity of cyclosporine. 
Dosage forms: Tablets, capsules as controlled release, drops and injection. 
Marketed preparations:  
Tablets: Dynapar, Diclomove, Inflamol, Valet, Udec, Fenbest.  
Capsules: Regunac 100mg. 
Drops: Icein, Diclolab, Diclol. 
Injections: Diclonip, Diclostar, Antiflam, Dicoliv. 
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5.2 EXCIPIENTS PROFILE 
5.2.1 Microcrystalline Cellulose37 
Synonyms: Avicel PH; cellulose gel; hellulosum microcristallinum; Celphere; Ceolus 
KG; crystalline cellulose; Emcocel; Ethispheres; Fibroce. 
Chemical Name: Cellulose 
Chemical structure:  
 
Nonproprietary names: 
BP: Microcrystalline Cellulose 
JP: Microcrystalline Cellulose 
PhEur: Cellulose, Microcrystalline 
USP-NF: Microcrystalline Cellulose 
Description: Microcrystalline cellulose is a white, odorless, tasteless, crystalline powder 
composed of porous particles.  
Melting point: Chars at 260 - 270°C 
Solubility: Slightly soluble in 5% w/v sodium hydroxide solution; practically insoluble 
in water, dilute acids, and most organic solvents. 
Functional Category: Adsorbent; suspending agent; tablet and capsule diluent; tablet 
disintegrant. 
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Applications: Microcrystalline cellulose is used in pharmaceuticals, as a binder/diluent 
in oral tablet and capsule formulations. 
Storage: Microcrystalline cellulose is a stable though hygroscopic material. The bulk 
material should be stored in a well-closed container in a cool, dry place. 
TABLE NO 4: PROPERTIES OF COMMERCIALLY AVAILABLE GRADES OF 
MICROCRYSTALLINE CELLULOSE 
Grade Nominal mean particle size 
Particle size analysis 
Moisture content 
(%) Mesh 
size 
Amount retained 
(%) 
Avicel pH 
101 50 
60 
200 
≤ 1.0 
≤ 30.0 ≤ 5.0 
Avicel pH 
102 100 
60 
200 
≤ 8.0 
≥ 45.0 ≤ 5.0 
Avicel pH 
103 50 
60 
200 
≤ 1.0 
≤ 30.0 ≤ 3.0 
Avicel pH 
105 20 400 ≤ 1.0 ≤ 5.0 
Avicel pH 
112 100 60 ≤ 8.0 ≤ 1.5 
Avicel pH 
113 50 
60 
200 
≤ 1.0 
≤ 30.0 ≤ 1.5 
Avicel pH 
200 180 
60 
100 
≥ 10.0 
≥ 50.0 ≤ 5.0 
Avicel pH 
301 50 
60 
200 
≤ 1.0 
≤ 30.0 ≤ 5.0 
Avicel pH 
302 100 
60 
200 
≤ 8.0 
≥ 45.0 ≤ 5.0 
 
Incompatibilities: Microcrystalline cellulose is incompatible with strong oxidizing 
agents. 
Chapter V                                                                                                   Preformulation 
Department of Pharmaceutics                       45       JKKMMRF College of Pharmacy 
5.2.2 Lactose Monohydrate36 
Synonyms: Capsulac; Granulac; Lactochem; Lactosum Monohydricum; Monohydrate; 
Pharmatose; PrismaLac; SacheLac, SorboLac, SpheroLac, SuperTab 30GR; Tablettose. 
Chemical Name: O-β-D-Galactopyranosyl-b-D-glucopyranose monohydrate 
Chemical structure:  
 
Nonproprietary names: 
BP: Lactose 
JP: Lactose Hydrate 
PhEur: Lactose Monohydrate 
USP-NF: Lactose Monohydrate 
Description: Lactose Monohydrate occurs as white to off-white crystalline particles or 
powder. Melting point: 201 - 202°C for dehydrated alpha lactose monohydrate 
Solubility: Soluble in water; practically insoluble in ethanol, chloroform and ether. 
Functional Category: Dry powder inhaler carrier; lyophilization aid; tablet binder; tablet 
and capsule diluents; tablet and capsule filler. 
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Applications: Lactose is widely used in dry powders and direct compression tabletting 
applications, and as a tablet and capsule filler and binder. 
Storage: Lactose should be stored in a well-closed container in a cool, dry place. 
Incompatibilities: Lactose monohydrate is incompatible with primary, secondary 
amines, amino acids and amfetamines. 
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5.2.3 Povidone40 
Synonyms: Kollidon; Plasdone; polyvidone; polyvinylpyrrolidone; povidonum; 
Povipharm; PVP; 1- vinyl-2-pyrrolidinone polymer.  
Chemical Name: 1-Ethenyl-2-pyrrolidinone homopolymer 
Chemical structure: 
 
Nonproprietary names: 
BP: Povidone 
JP: Povidone 
PhEur: Povidone 
USP: Povidone  
Description: Povidone occurs as a fine, white to creamy-white colored, odorless or 
almost odorless, hygroscopic powder. 
Melting point: Softens at 1508C. 
Solubility: Freely soluble in acids, chloroform, ethanol (95%), ketones, methanol, and 
water; practically insoluble in ether, hydrocarbons, and mineral oil.  
Functional Category: Disintegrant; dissolution enhancer; suspending agent; tablet 
binder. 
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Applications: In tabletting, povidone solutions are used as binders. Povidone is 
additionally used as a suspending, stabilizing, or viscosity-increasing agent in a number 
of topical and oral suspensions and solutions. 
Storage: Povidone is hygroscopic, should be stored in an airtight container in a cool, dry 
place. 
Incompatibilities: It forms molecular adducts in solution with sulfathiazole, sodium 
salicylate, salicylic acid, phenobarbital, tannin, and other compounds. 
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5.2.4 Ethyl Cellulose34 
Synonyms: Aqua coat ECD; Aqualon; Ashacel; Ethocel; ethylcellulosum; Surelease. 
Chemical Name: Cellulose ethyl ether  
Chemical structure:  
 
Nonproprietary names: 
BP: Ethyl cellulose 
PhEur: Ethyl cellulose 
USP-NF: Ethyl cellulose 
Description: It is a tasteless, free-flowing, and white to light tan-colored powder. 
Specific gravity: 1.12–1.15 g/cm3 
Solubility: Practically insoluble in glycerin, propylene glycol, and water. Ethyl cellulose 
that contains less than 46.5% of ethoxyl groups is freely soluble in chloroform, methyl 
acetate, and tetrahydrofuran, and in mixtures of aromatic hydrocarbons with ethanol 
(95%).  
Functional Category: Coating agent; flavoring agent; tablet binder; viscosity increasing 
agent. 
Applications: Ethyl cellulose is widely used as a hydrophobic coating agent for tablets 
and granules. 
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Storage: Ethyl cellulose is a stable, slightly hygroscopic material; it should be stored at a 
temperature not exceeding 328°C (908F) in a dry area away from all sources of heat. It 
should not be stored next to peroxides or other oxidizing agents. 
Incompatibilities: Incompatible with paraffin wax and microcrystalline wax. 
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5.2.5 Talc43 
Synonyms: Altalc; hydrous magnesium calcium silicate; hydrous magnesium silicate; 
Imperial; Magnesium hydrogen metasilicate; Magsil Osmanthus; Magsil Star; powdered 
talc; purified French chalk; Purtalc; soapstone; steatite; Superiore; talcum. 
Chemical Name: Octadecanoic acid magnesium salt 
Nonproprietary names: 
BP: Purified Talc 
JP: Talc 
PhEur: Talc 
USP: Talc  
Description: Talc is a very fine, white to grayish-white, odorless, impalpable, unctuous, 
crystalline powder. It adheres readily to the skin and is soft to the touch and free from 
grittiness. 
Moisture content: Talc absorbs insignificant amounts of water at 258C and relative 
humidity up to about 90%. 
Solubility: Practically insoluble in dilute acids and alkalis, organic solvents, and water. 
Functional Category: Antitacking agent; glidant; tablet and capsule diluent; tablet and 
capsule lubricant. 
Applications: Talc is also used as a lubricant in tablet formulations, adsorbent, 
dissolution retardant, and dusting powder.  
Storage: Talc should be stored in a well-closed container in a cool, dry place. 
Incompatibilities: Incompatible with quaternary ammonium compounds. 
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5.2.6 Isopropyl alcohol35 
Synonyms: Alcohol isopropylicus; dimethyl carbinol; IPA; isopropanol; petrohol; 2-
propanol; sec-propyl alcohol; rubbing alcohol. 
Chemical Name: Propan-2-ol 
Chemical structure: 
 
Nonproprietary names:  
BP: Isopropyl Alcohol 
JP: Isopropanol 
PhEur: Isopropyl Alcohol 
USP: Isopropyl Alcohol 
Description: Isopropyl alcohol is a clear, colorless, mobile, volatile, flammable liquid 
with a characteristic, spirituous odor resembling that of a mixture of ethanol and acetone. 
Melting point: 88.58°C 
Solubility: Miscible with benzene, chloroform, ethanol (95%), ether, glycerin, and water. 
Soluble in acetone; insoluble in salt solutions. 
Functional Category: Disinfectant; and solvent. 
Applications: Isopropyl alcohol (propan-2-ol) is used in cosmetics and pharmaceutical 
formulations, primarily as a solvent Isopropyl alcohol is also used as a solvent both for 
tablet film-coating and for tablet granulation, and topical disinfectant 
Storage: Isopropyl alcohol should be stored in an airtight container in a cool, dry place. 
Incompatibilities: Incompatible with oxidizing agents such as hydrogen peroxide and 
nitric acid, which cause decomposition. 
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5.2.7 Sunset Yellow42 
Synonyms: FD&C yellow #6; yellow orange S. 
Chemical Name: 6-hydroxy-5-[(4-sulfophenyl) azo]-2-naphthalenesulfonic acid 
disodium salt 
Chemical structure:  
 
 
 
 
 
 
 
Description: Reddish yellow powder. Aqueous solutions are bright orange colored. 
Color Index No: CI 15985 
Melting point: 300°C  
Solubility: soluble in water in the ratio of 1 in 63 at 25°C less soluble in glycerin and 
ethanol(75%) partially insoluble in acetone. 
Functional Category: Colouring agent.  
Applications: Sunset yellow is often used in conjunction with E123, amaranth, in order 
to produce colouring in both chocolates and caramel. 
Storage: It undergoes a phase change from an isotropic liquid to liquid crystal at room 
temperature. Store it in air tight light resistant container, cool, dry place.  
Incompatibilities: Poorly compatible with citric acid, saccharose solutions, and saturated 
sodium bicarbonate solutions. Incompatible with ascorbic acid, gelatin, and glucose. 
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5.2.8 Polyethylene Glycol 38  
Synonyms: Carbowax; Carbowax Sentry; Lipoxol; Lutrol E; macrogola; PEG 
Chemical Name: a-Hydro-o-hydroxypoly (oxy-1, 2-ethanediyl) 
Nonproprietary names: 
BP: Macrogols 
JP: Macrogol 400 
Macrogol 4000 
Macrogol 6000 
PhEur: Macrogols 
USP-NF: Polyethylene Glycol 
Description: Liquid grades (PEG 200–600) occur as clear, colorless or slightly yellow-
colored, viscous liquids. They have a slight but characteristic odor and a bitter, slightly 
burning taste. Solid grades (PEG>1000) are white or off-white in color, and range in 
consistency from pastes to waxy flakes. They have a faint, sweet odor. Grades of PEG 
6000 and above are available as free flowing milled powders. 
Moisture content: Liquid polyethylene glycols are very hygroscopic, solid grades, e.g. 
PEG 4000 and above, are not hygroscopic.  
Solubility: All grades of polyethylene glycol are soluble in water. Liquid polyethylene 
glycols are soluble in acetone, alcohols, benzene, glycerin, and glycols. Solid 
polyethylene glycols are soluble in acetone, dichloromethane, ethanol (95%), and 
methanol; they are slightly soluble in aliphatic hydrocarbons and ether, but insoluble in 
fats, fixed oils, and mineral oil. 
Functional Category: Ointment base; plasticizer; suppository base; tablet and capsule 
lubricant  
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Applications: Polyethylene glycol has been used experimentally in biodegradable 
polymeric matrices used in controlled-release systems. Solid grades are generally 
employed in topical ointments; Mixtures of polyethylene glycols can be used as 
suppository bases,  
Storage: Polyethylene glycols should be stored in well-closed containers in a cool, dry 
place. Stainless steel, aluminum, glass, or lined steel containers are preferred for the 
storage of liquid grades.  
Incompatibilities: all grades can exhibit some oxidizing activity, liquid and solid 
polyethylene glycol grades may be incompatible with some coloring agents. 
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5.2.9 Propylene Glycol41 
Synonyms 
1, 2-Dihydroxypropane; E1520; 2-hydroxypropanol; methyl ethylene glycol; methyl 
glycol; propane-1, 2-diol; propylenglycolum. 
Chemical Name: 1, 2-Propanediol 
Nonproprietary Names 
BP: Propylene Glycol 
JP: Propylene Glycol 
PhEur: Propylene Glycol 
USP: Propylene Glycol 
Description: Propylene glycol is a clear, colorless, viscous, practically odorless liquid, 
with a sweet, slightly acrid taste resembling that of glycerin. Solubility Miscible with 
acetone, chloroform, ethanol (95%), glycerin, and water; soluble at 1 in 6 parts of ether; 
not miscible with light mineral oil or fixed oils, but will dissolve some essential oils. 
Functional Category: Antimicrobial preservative; disinfectant; humectants; plasticizer; 
solvent; stabilizing agent; water-miscible cosolvent. 
Applications: Propylene glycol is commonly used as a plasticizer in aqueous film-
coating formulations.  
Storage: At cool temperatures, propylene glycol is stable in a well-closed container; it is 
hygroscopic and should be stored in a well closed container, protected from light, in a 
cool, dry place. 
Incompatibilities: Propylene glycol is incompatible with oxidizing reagents such as 
potassium permanganate. 
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5.2.10 Titanium Dioxide44 
Synonyms: Anatase titanium dioxide; brookite titanium dioxide; color index number 
77891; E171; Hombitan FF-Pharma; Kemira AFDC; Kronos 1171; pigment white 6; 
Pretiox AV-01-FG; rutile titanium dioxide; Tioxide; TiPure; titanic anhydride; titanii 
dioxidum; Tronox. 
Nonproprietary Names 
BP: Titanium Dioxide 
JP: Titanium Oxide 
PhEur: Titanium Dioxide 
USP: Titanium Dioxide 
Chemical Name: Dioxotitanium 
Description: White, amorphous, odorless, and tasteless nonhygroscopic powder. 
Although the average particle size of titanium dioxide powder is less than 1 mm, 
commercial titanium dioxide generally occurs as aggregated particles of approximately 
100 mm diameter. Titanium dioxide may occur in several different crystalline forms: 
rutile; anatase; and brookite. Of these, rutile and anatase are the only forms of 
commercial importance. Rutile is the more thermodynamically stable crystalline form, 
but anatase is the form most commonly used in pharmaceutical applications. 
Moisture content: 0.44% 
Solubility: Practically insoluble in dilute sulfuric acid, hydrochloric acid, nitric acid, 
organic solvents, and water. Soluble in hydrofluoric acid and hot concentrated sulfuric 
acid. Solubility depends on previous heat treatment; prolonged heating produces a less-
soluble material. 
Functional Category: Coating agent; opacifier; pigment. 
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Applications: Titanium dioxide is widely used in confectionery, cosmetics, and foods, in 
the plastics industry, and in topical and oral pharmaceutical formulations as a white 
pigment. 
Storage: Titanium dioxide should be stored in a well-closed container, protected from 
light, in a cool, dry place. 
Incompatibilities: Titanium dioxide has shown to induce photo oxidation of unsaturated 
lipids. 
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5.2.11. Dichloromethane 
Synonyms: Methylene chloride 
Nonproprietary Names 
BP: Methylene chloride 
PhEur: Methylene chloride 
USP: Dichloromethane 
Chemical Name: Methylene Dichloride 
Description: Clear, colorless, volatile liquid 
Moisture content: 0.05% m/m, determined on 10.0gm 
Solubility: Sparingly soluble in water miscible with ethanol (96%) 
Relative density: 1.320 – 1.332 
Refractive index: 1.423 – 1.425 
Functional Category: Solvent, Granulation liquid 
Applications: Dichloromethane used in pharmaceutical industry as a solvent and 
analytical reagent. 
Storage: In air tight container, protected from light 
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5.3. COATING POLYMER PROFILE 
5.3.1 Polymethacrylates39 
Synonyms: Acryl-EZE; acidi methacrylici et ethylis acrylatis polymerisatum; acidi 
methacrylici et methylis methacrylatis polymerisatum; ammonio methacrylatis 
copolymerum; copolymerum methacrylatis butylati basicum; Eastacryl; Eudragit; 
Kollicoat MAE; polyacrylatis dispersio 30 per centum; polymeric methacrylates. 
Nonproprietary Names 
BP: Ammonio Methacrylate Copolymer (Type A) 
Ammonio Methacrylate Copolymer (Type B) 
Methacrylic Acid–Ethyl Acrylate Copolymer (1: 1) 
Methacrylic Acid–Methyl Methacrylate Copolymer (1: 1) 
Methacrylic Acid–Methyl Methacrylate Copolymer (1: 2) 
PhEur: Ammonio Methacrylate Copolymer (Type A) 
Ammonio Methacrylate Copolymer (Type B) 
Basic Butylated Methacrylate Copolymer 
Methacrylic Acid–Ethyl Acrylate Copolymer (1: 1) 
Methacrylic Acid–Methyl Methacrylate Copolymer (1: 1) 
Methacrylic Acid–Methyl Methacrylate Copolymer (1: 2) 
USP-NF: Amino Methacrylate Copolymer 
Ammonio Methacrylate Copolymer 
Methacrylic Acid Copolymer 
Chemical Name: Poly (methacrylic acid, methyl methacrylate)  
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Structure: 
 
Description: Polymethacrylates are synthetic cationic and anionic polymers of 
dimethylaminoethyl methacrylates, methacrylic acid, and methacrylic acid esters in 
varying ratios. Several different types are commercially available and may be obtained as 
the dry powder, as an aqueous dispersion, or as an organic solution. Eudragit L and S, 
referred to as methacrylic acid copolymers in the USP32–NF27 monograph, are anionic 
copolymerization products of methacrylic acid and methyl methacrylate. The ratio of free 
carboxyl groups to the ester is approximately 1: 1 in Eudragit L (Type A) and 
approximately 1: 2 in Eudragit S (Type B). Both polymers are readily soluble in neutral 
to weakly alkaline conditions (pH 6–7) and form salts with alkalis, thus affording film 
coats that are resistant to gastric media but soluble in intestinal fluid. They are available 
as a 12.5% solution in propan-2-ol without plasticizer. Eudragit L 100-55 (prepared by 
spray-drying Eudragit L 30 D- 55) is a white, free-flowing powder that is redispersible in 
water to form latex that has properties similar to those of Eudragit L 30 D- 55. 
Viscosity (dynamic): 50–200 mPa s for Eudragit L and S; 415 mPa s for Kollicoat MAE 
100 P  
Solubility: soluble acetone, alcohol and in gastric fluid to pH 5.0 and 5.5  
Functional Category: Film-forming agent; tablet binder; tablet diluent. 
Applications: Polymethacrylates are primarily used in oral capsule and tablet 
formulations as film-coating agents.(1–21) Depending on the type of polymer used, films 
of different solubility characteristics can be produced; Eudragit L,  used as enteric coating 
Chapter V                                                                                                   Preformulation 
Department of Pharmaceutics                       62       JKKMMRF College of Pharmacy 
agents because they are resistant to gastric fluid. Different types of enteric coatings are 
soluble at different pH values: e.g. Eudragit L is soluble at pH > 6 whereas Kollicoat 
MAE 100 P, commercially available as redispersible powder forms, which are designed 
for enteric coating of tablets or beads. 
Storage: Dry powder polymer forms are stable at temperatures less than 30°C. Above 
this temperature, powders tend to form clumps, although this does not affect the quality 
of the substance and the clumps can be readily broken up. Dry powders are stable for at 
least 3 years if stored in a tightly closed container at less than 30°C. Dispersions are 
sensitive to extreme temperatures and phase separation occurs below 0°C.  
Incompatibilities: Incompatibilities occur with certain polymethacrylate dispersions 
depending upon the ionic and physical properties of the polymer and solvent. For 
example, coagulation may be caused by soluble electrolytes, pH changes, some organic 
solvents, and extremes of temperature; Kollicoat MAE 100 P is incompatible with 
magnesium stearate. 
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6. MATERIALS AND EQUIPMENTS 
6.1. TABLE 5: List of Materials 
S.No                  Materials Manufacturers and suppliers 
   1 Diclofenac sodium Sigma Aldrich, Bangalore 
   2  Ethyl cellulose Lab chemicals, Chennai 
   3  Povidone (PVP – K30) Lab chemicals, Chennai 
   4 Microcrystalline cellulose Paxmy specialty chemicals, Chennai 
   5 Lactose anhydrous  Chemspure, Chennai 
   6 Eudragit L100 BASF,Germany 
   7 Kollicoat MAE 100P BASF,Germany 
   8 Propylene glycol Lab chemicals,Chennai 
   9 Titanium dioxide Sigma Aldrich,Bangalore 
  10 Polyethylene glycol Chemspure,Chennai 
  11 Methylene chloride Sigma Aldrich,Bangalore 
  12 Isopropyl alcohol Sigma Aldrich,Bangalore 
  13 Purified Talc Chemspure, Chennai 
  14 Sunset yellow Sigma Aldrich, Bangalore 
  15 Hydrochloric acid S.d. Fine chemicals ltd, Mumbai 
   16 Sodium hydroxide S.d. Fine chemicals ltd, Mumbai 
   17 Potassium di hydrogen phosphate S.d. Fine chemicals, Mumbai 
   18 Potassium chloride Chemspure, Chennai 
   19 Ethanol S.d. Fine chemicals, Mumbai 
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6.2. TABLE 6: List of Equipments 
S.No                      Equipments                          Manufacturer 
1 Digital balance Axis LE/GC, India 
2 Digital pH meter Model 111E Electrolab, Mumbai 
3 UV – visible spectrophotometer Shimadzu UV – 1601, Japan 
4 FT – IR spectrophotometer MB 104 Shimadzu corporation,japan 
6 Dissolution tester Electrolab TDT – 08L, Mumbai 
7 Hot air oven Minicon, Mumbai 
8 Humidity cabinet Sigma instruments, Mumbai 
9 High precision balance Infra, India 
10 Friabilator (USP) EF 2 Electrolab, Mumbai 
11 Laboratory centrifuge 2C Remi, India 
12 Table sieve shaker CAT. 510 Secor, India 
13 Screw feed Extruder  
14 Marumerizer  
15 Coating pan  
16 Differential scanning calorimetry  
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7. FORMULATION AND EVALUATION 
7.1. Preparation of Diclofenac Sodium Core Pellets 
1) Sifting   : Diclofenac sodium, microcrystalline cellulose PH 101,  
   Lactose were sifted through 24# SS screen mesh and  
   transferred to planetary mixer (PLM 200).  
2) Mixing  : The materials of stage 1 were mixed thoroughly for 30  
   minutes in a planetary mixer. 10% of mixed materials is  
   taken out for dusting purposes in the forthcoming   
   marumarization stage  
3) Binder preparation : Povidone K 30 was prepared as 9% w/v solution with the  
   help of water. The binder solution of stage 3 was added to  
   stage 2 and until a cohesive mass was obtained. 
4) Extrusion  : The cohesive mass prepared at stage 3 was loaded to  
   Screw-feed extruder using 0.9mm mesh screen.   
   Adjustments are made in the machine and the cohesive  
   mass prepared was obtained as vermicelli type extrusions. 
5) Marumarization : The prepared extrudates were passed to marumerizer and  
   operated at a speed of 1400 rpm for 4-6 minutes. 10% of  
   stage I materials were used as dusting powder. Operation  
   was continued until good spherical pellets are obtained 
6) . Drying  : The pellets obtained in stage 5 dried at 40o C for 3 hours  
   in fluidized bed dryer. The pellets were kindled at the  
   interval of one hour to ensure uniform drying. 
7) Sizing   : Dried pellets were passed through 12# and fraction  
   retained on 24# was collected for further characterization. 
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SCHEMATIC REPRESENTATION OF FABRICATION METHODOLOGY 
 
Chapter VII                                                                          Formulation and evaluation 
Department of Pharmaceutics                       67       JKKMMRF College of Pharmacy 
TABLE 7: Formulation of Diclofenac Sodium Core Pellets 
 
From formulation 1 (F1) to formulation 6 (F6), excipients were altered at different 
concentration to obtain desired pellets, while the active pharmaceutical ingredient was 
kept constant in all the formulations. 
                              Where, 
mg - milligrams; Cap - Capsule 
 
 
S.NO 
INGREDIENTS F1 (mg/cap) 
F2 
(mg/cap) 
F3 
(mg/cap) 
F4 
(mg/cap) 
F5 
(mg/cap) 
F6 
(mg/cap) 
1. DICLOFENAC SODIUM 100 100 100 100 100 100 
2. 
MICRO 
CRYSTALLINE 
CELLULOSE 
66 79 92 105.60 99 99 
3. POVIDONE K30 3.3 6.6 9.9 13.2 9.9 9.9 
4. LACTOSE 160.7 144.4 128.1 111.20 128.10 128.10 
5. TOTAL 330 330 330 330 330 330 
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FIGURE 9: Extrudates of Diclofenac Sodium 
      
(A)                                                                   (B) 
 
(C) 
Where, A Depicts Screw feeder extruder, B Depicts Processing extrudate, C Depicts 
Finished Extrudate  
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7.1.1. Coating Methodology for Pellets 
TABLE 8: Formulation For Coating with Kollicoat MAE 100P 
INGREDIENTS 
C1 
(mg/cap) 
C2 
(mg/cap) 
C3 
(mg/cap) 
C4 
(mg/cap) 
KOLLICOAT MAE 100P 33.0 33.0 49.5 49.5 
ETHYL CELLULOSE _ 6.6 _ 6.6 
PROPYLENE GLYCOL 6.75 6.75 6.75 6.75 
TITANIUM DIOXIDE 1.5 1.5 1.5 1.5 
TALC 12 12 12 12 
SUNSET YELLOW 1.5 1.5 1.5 1.5 
PURIFIED WATER 0.25 0.25 3.75 3.75 
ISOPROPYL ALCOHOL _ 33.0 _ 33.0 
METHYLENE DI CHLORIDE _ 33.0 _ 33.0 
 
STEP 1: Preparation of polymer suspension:  
Kollicoat MAE 100P is dispersed in specified amount of water. When it is completely 
dispersed the plasticizer propylene glycol is incorporated. 
STEP2: Preparation of pigment suspension:    
Sunset yellow, titanium dioxide and talc are intensively stirred into specified amount of 
water and homogenized. 
STEP3: Preparation of final solution   
The pigment suspension is stirred into the coating suspension .The spray suspension must 
be stirred during spraying to prevent the solid substances settling out. 
STEP 4: Preparation of sub coating solution: 
Weighed quantity of ethyl cellulose was dissolved in isopropyl alcohol and 
methylene dichloride in 1:1 ratio as sub coat solution. Prepared sub coat solution sprayed 
to the pellets prior to enteric coating process. 
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TABLE 9 : Formulation For Coating With Eudragit L 100 
INGREDIENTS 
C5 
(mg/cap) 
C6 
(mg/cap) 
C7 
(mg/cap) 
C8 
(mg/cap) 
EUDRAGIT L 100 33.0 33.0 49.5 49.5 
ETHYL CELLULOSE _ 6.6 _ 6.6 
POLY ETHYLENE GLYCOL 
6000 6.75 6.75 6.75 6.75 
TITANIUM DIOXIDE 1.5 1.5 1.5 1.5 
TALC 12 12 12 12 
SUNSET YELLOW 1.5 1.5 1.5 1.5 
ACETONE 0.220 0.220 0.220 0.220 
ISOPROPYL ALCOHOL 0.330 33.330 0.330 33.330 
METHYLENE DI CHLORIDE _ 33.0 _ 33.0 
 
Preparation of EUDRAGIT L 100 enteric coating solution: 
STEP 1: Preparation of diluents mixture: 
Diluent mixture is prepared by mixing specific quantities of acetone and isopropanol as 
per the table no: 9   
STEP2: Preparation of Eudragit solution: 
Specified amount of Eudragit L 100 is added slowly into 50% of diluent mixture and 
stirred for 30-60 minutes until the polymer is completely dissolved. 
STEP3: Preparation of excipients suspension  
Specified amount of talc and plasticizer poly ethylene glycol 6000 is added to remaining 
diluents mixture and stirred for 10 minutes in high shear mixer. 
STEP4: Preparation of final enteric coating solution  
The excipient suspension is poured slowly into Eudragit solution while it is stirred with a 
stirrer. Finally the spray suspension is passed through 0.5 mm sieve and used for coating.  
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TABLE 10: COATING SPECIFICATIONS 
S.NO COATING  PARAMETERS KOLLICOAT 
MAE 100P 
EUDRAGIT L 100 
           EQUIPMENT SET UP 
    1. COATING PAN 8”STAINLESS 
STEEL COATING 
PAN 
8”STAINLESS 
STEEL COATING 
PAN 
    2. SIZE OF BATCH           1 KG              1KG 
    3.  DRUM SPEED         8-10rpm             8-10 rpm 
    4. NUMBER OF SPRAY GUNS               1                1 
    5. NOZZLE BORE          1.2 mm             1.2 mm 
   6. DISTANCE PELLET 
BED/SPRAY GUN 
            10 cm             10cm 
PROCESS DATA 
   7.  INLET AIR  
TEMPERATURE 
            60 o C             50 o C 
   8. EXHAUST AIR 
TEMERATURE 
         25 o -30 o C           25 o -30 o C 
   9. PRODUCT TEMPERATURE          32 o -35 o  C          25 o -30 o C 
   10. SPRAY RATE           40 g/min            3-6 g/min 
  11. FINAL DRYING AT 40 C              2 hrs            2 hrs 
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PHOTOGRAPHS OF PREPARED DICLOFENAC SODIUM CORE AND 
ENTERIC COATED CAPSULES 
    
A) DICLOFENAC SODIUM CORE PELLETS 
 
B) DICLOFENAC SODIUM ENTERIC COATED PELLETS      
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7.2. EVALUATION PARAMETERS AND PROCEDURE FOR CORE AND 
ENTERIC COATED   PELLETS33 
Powder flow 
Pharmaceutical industry has generated a variety of methods to characterize flow 
of powder or granules. The development of such a variety of test methods was inevitable; 
powder behavior is multifaceted and thus complicates the effort to characterize powder 
flow. In spite of the complications an attempt has been made to characterize the flow 
property of the powder or granules with these methods. The most frequently used 
methods are angle of repose, compressibility index and hausner ratio. 
7.2.1 Angle of repose 
The angle of repose has been used in several branches of science to characterize 
the flow properties of solids. Angle of repose is a characteristic related to interparticulate 
friction or resistance to movement between particles.  
Procedure 
Angle of repose was done by using a funnel on a fixed base with retaining tip to 
retain a layer of the powder on the base. Height of the funnel was carefully built up a 
symmetrical cone of granules and it was freed from vibration. Care was taken to prevent 
vibration as the funnel is moved. The funnel height was maintained approximately 2- 4 
cm from the top of the granules pile as it is being formed in order to minimize the impact 
of the falling powder on the tip of the cone.   
Angle of repose was determined by measuring the height of the cone of powder 
and calculating the angle of repose  
 
Where,  
h = Height of the cone; r = Radius of surface area of the pile. 
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 7.2.2 Bulk density and tapped density: 
An accurately weighed quantity of the pellets (w), which was previously passed 
through 40#, was carefully poured into the graduated cylinder and the volume (v0) was 
measured. The graduated measuring cylinder was tapped for 100 times, volume (vf) was 
measured and continued the operation till the two consecutive readings were equal. Bulk 
density and tapped density were calculated using the formula given below, 
  
Where,  
          W = weight of the pellets; V0 = initial volume; Vf = final volume  
TABLE 11: Flow properties and corresponding angle of repose 
Flow property Angle of repose ( degrees ) 
Excellent 25 – 30 
Good 31 – 35 
Fair – aid not needed 41 – 45 
Passable – may hung up 41 – 45 
Poor – must agitate, vibrate 46 – 55 
Very poor 56 – 65 
Very, very poor > 66 
 
7.2.3 Compressibility index 
The compressibility index has been proposed as an indirect measure of bulk 
density, size, shape, surface area, moisture content, and cohesiveness of materials 
because all of these can influence the observed compressibility index. 
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Procedure 
Compressibility index of the pellets was determined by measuring both the bulk 
volume and the tapped volume of the pellets. On preference, measured the unsettled 
apparent volume V0, and final tapped volume Vf, of the pellets until no further volume 
changes occur on tapping using 250ml volumetric cylinder with 100g of pellets. The 
compressibility index was calculated with the following equation, 
 
 Alternatively, the compressibility index can be calculated using measured values 
for bulk density (ρbulk) and tapped density (ρtapped) by following equation 
 
7.2.4 Hausner’s ratio 
It is a number that is correlated to the Flowability of the powder or granular 
material. In recent years the hausner ratio has become the simple, fast, and popular 
methods of predicting powder flow characteristics.  
Procedure  
The hausner ratio and compressibility index are determined by measuring both the 
bulk volume and the tapped volume of the powder. Hausner’s was calculated with the 
following formula. 
 
Alternatively it can be calculated by following equation,  
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TABLE 12: Scale of Flowability 
Compressibility index (%) Flow character Hausner ratio (g/ml) 
<10 Excellent 1.00 – 1.11 
11 – 15 Good 1.12 – 1.18 
16 – 20 Fair 1.19 – 1.25 
21 – 25 Passable 1.26 – 1.34 
26 – 31 Poor 1.35 – 1.45 
32 – 37 Very poor 1.46 – 1.49 
>38 Very, very poor >1.60 
 
7.2.5 Friability: 15  
Friability of pellets were tested using an  Abrasion drum which is a modified 
USP friability tester .This drum can generate two different types of motion depending on 
how the abrasion drum is mounted to the friabilator arm. One motion generates cascading 
movement from one lamella to other, while the other motion raises and drops the spheres 
from a distance approx 200 mm. 
Procedure 
10 gm of pellets are weighed initially and taken as w1, placed in a friabilator and 
rotated for 25 rpm for 10 minutes. Pellets were re-weighed after the removal of fines and 
noted as w2. The percentage of weight loss was calculated by the following equation. As 
per the IP official limit friability should not be more than 1% 
00 
Where,    w1 = Initial weight of pellets; w2 = Final weight of pellets 
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7.2.6 Sieve analysis: 32 
        The sieves used in analysis were weighed individually. Sieve number 18, 20, 24 
were used for analysis.100 gm of sample weighed separately. Sieves were cleaned and 
assembled in ascending order of sieve numbers (18, 20, and 24). A receiving pan was 
placed below 24# sieve. Carefully the sample is placed onto the top sieve. The sieve stack 
is placed in mechanical shaker and operated for 10 minutes. The stack is removed from 
shaker and weight of each sieve with its retained sample was weighed. 
        The percentage of sample retained in each sieve is calculated by formula: 
                            % Retained   =     
       The percentage of sample passed from each sieve is calculated by formula: 
                                          % Passing     =     100 - % Retained  
7.2.7 Loss on drying: 25 
One gm of pellets was weighed in a petriplate and noted it as S1. Weighed pellets 
were dried in oven for three hours at 105° C. After three hours petriplate was taken out 
and reweighed and noted it as S2. The percentage of weight loss after drying was 
calculated as per the following formula, 
                 Percentage loss =   
Where,   S2-S1  = Weight loss of the pellets 
                 S2    =   Weight of sample after drying 
                               S1   =   Weight of sample before drying 
7.2.8 Drug content 10 
                 Weigh initially 5 gm of sample, crushed the pellets in a mortar and weighed 
accurately a quantity equivalent to 50 mg of Diclofenac sodium and shaken with 60 ml of 
methanol in 200 ml volumetric flask and diluted the volume with methanol. 5ml of this 
solution is diluted to 100 ml with methanol. The absorbance of resulting solution is 
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measured at maximum about 285 nm. The content of Diclofenac sodium is calculated 
from the absorbance obtained by repeating the procedure using Diclofenac sodium RS in 
place of substance.                   
7.3 EVALUATION OF CAPSULES FILLED WITH DICLOFENACSODIUM 
CORE PELLETS 
7.3.1Weight variation 61 
    Twenty capsules were selected at randomly, weighed individually and an average 
weight is calculated. Not more than two capsules should deviate from average weight by 
more than the percentage given in standard table no 13 and none of the capsule should 
deviate by more than double the percentage given in standard table as per I.P. 
TABLE 13: I.P.OFFICIAL LIMITS 
S.NO Average weight of capsule Percentage variation 
1. More than  300 mg ±7.5% 
2. Less than   300 mg ±10% 
 
7.3.2 Drug content 10 
              Randomly selected 10 capsules from a trial emptied the contents into a mortar. 
Crushed contents were weighed  accurately a quantity of  powder equivalent to 50 mg of 
Diclofenac sodium was shaken  with 60 ml of methanol in 200 ml volumetric flask and 
diluted the volume with methanol. 5ml of this solution is diluted to 100 ml with 
methanol. The absorbance of resulting solution is measured at maximum about 285 nm. 
The content of Diclofenac sodium is calculated from the absorbance obtained by 
repeating the procedure using Diclofenac sodium RS in place of substance under 
examination.  I.P Limit for assay is 90-110%.  
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7.3.3 Content uniformity 
               To ensure the consistency of dosage units, each unit should have drug content 
within a narrow range around   the label claim. Content uniformity is defined as degree of 
uniformity in amount of drug substance among dosage units. 
Procedure 
Ten capsules were randomly selected from each trial; contents were removed 
from each capsule and assayed individually. The percentage of drug present in each 
individual capsule is calculated.  All the capsules should comply the test and should be 
within I. P Limit. Limit is 90-110%.  
7.3.4 Invitro dissolution test 
Dissolution studies were carried out by USP type I method at 37±5oC, taking 900 
ml of phosphate buffer of pH 6.8 at 50 rpm. The test sample of 5ml was withdrawn at 
specific interval (15, 30, and 45 minutes) and replaced with fresh dissolution medium. 
The test sample was filtered and diluted with 100 ml of buffer medium. The 
concentration of dissolved drug was determined using U.V. spectrophotometer at 285 nm. 
These results are given in table no: 23 
7.4  EVALUATION OF CAPSULES FILLED WITH DICLOFENACSODIUM 
ENTERIC COATED PELLETS: 
7.4.1 Weight variation 
           Twenty capsules were selected at random ,weighed individually and an average 
weight is calculated  not more than two capsules deviate from average weight by more 
than the percentage given in standard  table and none of the capsule deviates by more 
than double the percentage given in standard  table no: 14 
TABLE 14: I.P.OFFICIAL LIMITS 
S.NO Average weight of capsule Percentage variation 
1. More than  300 mg ±7.5% 
2. Less than   300 mg ±10% 
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7.4.2 Drug content 
             Randomly selected 10 capsules from a trial emptied the contents into a mortar. 
Crushed the contents and  weighed  accurately a quantity of  powder equivalent to 50 mg 
of Diclofenac sodium ,shaken  with 60 ml of methanol in 200 ml volumetric flask and 
diluted the volume with methanol. 5ml of this solution is diluted to 100 ml with 
methanol. The absorbance of resulting solution is measured at maximum about 285 nm. 
The content of Diclofenac sodium is calculated from the absorbance obtained by 
repeating the procedure using Diclofenac sodium RS in place of substance under 
examination. As per I.P. assay limit is 90 – 110%. 
7.4.3 Content uniformity 
            To ensure the consistency of dosage units, each unit should have drug content 
within a narrow range around the label claim.  
Procedure 
Ten capsules were randomly selected from each trial; contents were removed 
from each capsule and assayed individually. The percentage of drug present in each 
individual capsule is calculated.  All the capsules should comply the test and within I. P 
Limit. Limit is 90-110% 
7.4.4 In vitro dissolution test  
In vitro dissolution studies were carried out using USP Type I apparatus at 50 
rpm. The dissolution medium consisted of 900 ml pH 0.1N Hydrochloric acid buffer for 
first two hours and then it was replaced with 900ml of pH 6.8 phosphate buffer 
maintained at 37 ± 0.5°C.  Withdrawn suitable volume of test solution and it was 
replaced with fresh buffer, absorbance was measured at 285 nm. 
7.4.5 Scanning electron microscopy49 
Scanning electron microscopy is an electron optical imaging technique that yields 
both topographic images and elemental information. SEM is useful for characterizing the 
size and morphology of microscopic specimens. Typically SEM analysis requires a small 
amount (10 10-1012) of solid specimen that is coated with conductive substance to inhibit 
sample charging.  
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             The sample is placed is placed in evacuated chamber and scanned in raster 
pattern by electron beam.  Interaction of electron beam with specimen produces a variety 
of physical phenomena that, when detected, used to form images and provide elemental 
information. These phenomena include (1) emission of secondary electrons (2) Reflection 
of back scattered electrons.(3) Characteristic X-Ray emission (4)Emission of auger 
electrons (5)Cathadoluminescence  (6) Conduction of current (7) Charging from induced 
voltages (8)Electron- transmission (9) Heat generation  and  (10) Electromotive forces. 
Procedure 
The particle size and morphology of Diclofenac sodium Core and Enteric Coated 
pellets were analyzed through SEM Analysis. Samples from final optimized batches of 
core and coated pellet formulations ( F6 & C8) were mounted on aluminium  stubs using 
double sided sticky tape,  vaccum coated  with gold film (Polaron SC 500 sputter coater) 
and examined using Scanning Electron Microscope ( Leo Stereoscan  S-360). 
7.5. STABILITY STUDIES 
Stability of a drug has been defined as the ability of a particular formulation, in a 
specific container, to remain within is physical, chemical, therapeutics and toxicological 
specifications. Stability studies were conducted for the optimized enteric coated pellet 
formulation. The reason for selection is, formulation have shown good results in invitro 
drug release studies. The stability was performed as per following. 
7.5.1 Preliminary stability of the optimized batch 
The optimized batch (C8) was charged on accelerated stability as per ICH guidelines. 
TABLE 15: Stability protocol of enteric coated Diclofenac sodium capsules 
S.No Study Storage condition 
1 Long term 25°C ± 2°C / 60% RH ± 5% RH 
2 Intermediates 30°C ± 2°C / 60% RH ± 5% RH 
3 Accelerated 40°C ± 2°C / 75% RH ± 5% RH 
7.5.2 Testing parameters: Appearance, colour change, friability and drug content was 
tested after a period of 60 days.   
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8. RESULTS AND DISCUSSION 
In the present work Capsule dosage form containing Diclofenac sodium enteric coated 
pellets were prepared by using Extrusion – Marumarization technique for the fabrication 
of Diclofenac sodium pellets and enteric coated with enteric polymer for the treatment of 
Osteoarthritis and Rheumatoid arthritis. 
 8.1. Preformulation 
Preformulation data are vital for decision making on the choice of dosage form 
and excipients and essential for preceding it further for the development of dosage form. 
 8.1.1. Characterization of active pharmaceutical ingredient and polymer 
Drug (Diclofenac sodium), Diluents (MCC Ph101), Binder (PVP K30), Filler 
(Lactose), were characterized by using Fourier Transform Infra Red Spectroscopy. 
Diclofenac sodium was analyzed under IR spectra and their results were produced 
in figure no: 10. The mixture of API with Lactose, API with PVP  K30, API with MCC, 
and their mixture were characterized through IR spectrum and their spectra were given in 
figure no: 11, 12, 13 and 14 respectively. The resulted IR spectra were interpreted and 
presented. The results match the test sample when compared with reference standard. 
TABLE 16: Interpretation of IR Spectrum for Diclofenac Sodium 
S.NO Functional group Wave number cm-1 
1            NH Stretching 3209.66-3446.91 
2 CH Bend in plane 1400.37-1456.30 
4 C=C 1504.53-1572.04 
5 C-C Stretching 840.99-1089.82 
6 C-NH
 
1180.47-1296.21 
7 Cl2 624.96-750.33 
 
Chapter VIII                                                                                 Results and Discussion 
Department of Pharmaceutics                       83     JKKMMRF College of Pharmacy 
Diclofenac sodium showed a prominent IR absorption band in the region of 
3209.66, 3446.91 cm-1 due to urea NH stretching, a very sharp peak observed at 1400.37, 
1456.30cm-1 due to –CH Bend in plane of Benzene ring, at 1504.53, 1572.04 cm-1 the 
absorption was due to C=C, a strong absorption band s at 840.99-1089.82 cm-¹ due to C-
C Stretching, at 1180.47-1296.21 cm-1 due to C-NH was observed. The absorption peak 
of chlorine occurred at 624.96, 750.33 cm-1. 
8.1.2 Thermal analysis for characterizing interaction between drug and excipients 
Differential scanning calorimetry was done for the crude drug and its mixture 
with excipients. The resulted spectra with their melting points were given in figure no: 15 
& 16 respectively. Result showed there were presence of an exothermic peak at 285.43° 
C this attributes to the presence of Diclofenac sodium shown in figure no:15,  thermal 
curve for mixture of drug and excipients exhibited a sharp exothermic effect, at 164.31° 
C, 216.44, 269.27. These DSC curves indicate the melting points of for polyvinyl 
pyrolidone, Micro crystalline cellulose and Lactose. DSC results indicate there were 
presence no interactions between the drug and excipients.  
8.1.3 Analysis of Drug Excipient compatibility studies 
       The drug-excipient compatibility studies were determined in 1:1 ratios under 
Humidity Cabinet at different temperature and humidity conditions for the period of four 
weeks and the results showed that there was no physical change in appearance, color and 
odor. The results were given in table no: 17 
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FIGURE 10: FT - IR Spectral Analysis for Diclofenac Sodium 
 
FIGURE 11: FT - IR Spectral Analysis for Diclofenac Sodium with Lactose 
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FIGURE 12: FT - IR Spectral Analysis for Diclofenac Sodium with Microcrystalline 
cellulose 
 
FIGURE 13: FT - IR Spectral Analysis for Diclofenac Sodium with   PovidoneK30  
 
 
 
Chapter VIII                                                                                 Results and Discussion 
Department of Pharmaceutics                       86     JKKMMRF College of Pharmacy 
FIGURE 14: FT - IR Spectral Analysis for Diclofenac Sodium with Microcrystalline 
cellulose, polyvinyl pyrolidone and Lactose 
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FIGURE 15: Differential Scanning Calorimetry Spectral Analysis of Diclofenac 
Sodium 
 
 
FIGURE 16: Differential Scanning Calorimetry Spectral Analysis of Diclofenac 
Sodium with Excipient mixture 
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Table 17: Analysis of Excipients Compatibility by Stability Studies 
S.NO DRUG + EXCIPIENT RATIO INITIAL 
CONDITIONS 
COMMENTS RT40°C/75%RH  RT 60°/90%RH 
2Weeks  4Weeks 2Weeks  4Weeks 
1 
Diclofenac Na 
+ 
Microcrystalline 
cellulose 
 pH 101 
1:1 
White 
color 
powder 
No 
colour 
change 
No 
colour 
change 
No 
colour 
change 
No 
colour 
change 
Compatible 
2 
Diclofenac Na 
+  
Pyro vinyl 
pyrolidone  
K 30 
1:1 
White 
color 
powder 
No 
colour 
change 
No 
colour 
change 
No 
colour 
change 
No 
colour 
change 
Compatible 
3 
Diclofenac Na+ 
Lactose 
monohydrate 
1:1 
White 
color 
powder 
No 
colour 
change 
No 
colour 
change 
No 
colour 
change 
No 
colour 
change 
Compatible 
4 
Diclofenac Na 
+ Ethyl 
cellulose 
1:1 
White 
color 
powder 
No 
colour 
change 
No 
colour 
change 
No 
colour 
change 
No 
colour 
change 
Compatible 
5 
Diclofenac Na  
+ 
Kollicoat MAE 
100P  
1:1 
White 
color 
powder 
No 
colour 
change 
No 
colour 
change 
No 
colour 
change 
No 
colour 
change 
Compatible 
6 
   Diclofenac 
    Na + 
   Eudragit L100     
1:1 
White 
color 
powder 
No 
colour 
change 
No 
colour 
change 
No 
colour 
change
  
No 
colour 
change 
Compatible 
7 
Diclofenac Na 
+  
Titanium 
dioxide 
1:1 
White 
color 
powder 
No 
colour 
change 
No 
colour 
change
  
No 
colour 
change 
No 
colour 
change 
Compatible 
8 
   Diclofenac             
Na +   Talc  
 
1:1 White powder 
No 
colour 
change 
No 
colour 
change 
No 
colour 
change 
No 
colour 
change 
Compatible 
9 Diclofenac Na+ Sunset yellow 1:1 
Orange 
colour 
powder 
No 
colour 
change 
No 
colour 
change 
No 
colour 
change 
No 
colour 
change 
Compatible 
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8.1.4 Standard curve for Diclofenac sodium 
Standard curve for Diclofenac sodium were done by ultraviolet spectroscopy 
within the range of 200 – 400nm. 
The results for standard curve of Diclofenac sodium  in 0.1N Hydrochloric acid 
buffer and pH 6.8 phosphate buffer were shown in graph no: 1 & 2  and table no:18 & 19  
respectively.  
Straight line equation for Diclofenac Sodium in 0.1N Hydrochloric acid buffer; 
0.4356 = 0.0291 (15) - 0.0011 
Straight line equation for Diclofenac Sodium in pH 6.8 phosphate buffer;  
                                                    0.1294 = 0.0086 (15) + 0.0004 
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TABLE 18: Calibration Curve of Diclofenac Sodium in 0.1N HCl 
S.NO Concentration in µ/ml Absorbance at 285 nm 
1. 5 0.144 
2. 10 0.290 
3. 15 0.435 
4. 20 0.580 
5. 25 0.729 
 
          GRAPH: 1 Calibration Curve of Diclofenac Sodium in 0.1N Hydrochloric Acid 
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TABLE 19: Calibration Curve of Diclofenac Sodium in Ph 6.8 Phosphate Buffer 
S.NO Concentration in µgm/ml Absorbance at 285 nm 
1. 5 0.043 
2. 10 0.088 
3. 15 0.132 
4. 20 0.175 
5. 25 0.216 
 
 
GRAPH: 2 Calibration Curve of Diclofenac Sodium in Ph 6.8 Phosphate Buffer 
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8.2. Evaluation of Core Pellets (F1-F6) 
The micromeritic properties such as angle of repose, Bulk density, Tapped 
density, Carr’s index and Hausner’s ratio, Sieve analysis for uncoated core pellets were 
studied. The overall results were tabulated in table no: 20 
The pellets formulated from trial F1 found to be sticky .Therefore trial F1does not 
supported for further studies.  The bulk density and tapped density of formulations F2-F6 
ranged from 0.588 to 0.754gm/ml,0.675 to 0.785 gm/ml respectively. The angle of repose 
of the formulations F1-F6 was found in the range between 52.56 -26.56. Among those 
formulations F4, F5and F6 shows good and excellent flow character, while F2 and 
F3shows poor flow. 
The percentage of Carr’s index was found to be 22.94, 16.45 and 10.57, 9.09 and 
8.98. Formulation F2shows passable, F3 and F4 shows fair, F5and F6 shows excellent 
flow characteristics.  
Hausner’s ratio ranged from 1.34-1.06 and the formulations F2, F3, F4, F5, and 
F6 depicts the results 1.34, 1.19, 1.06, 1.04, 1.02. Among this five formulation F4, F5and 
F6 showed excellent flow character F2 and F3 showed fair and passable flow character. 
Sieve analysis was performed in a sieve shaker with a set of sieves (18, 20, and 
24) to determine the percentage of pellets obtained during the process. Trial F2 shows 8.4 
% in mesh 18, 3.4% in mesh 20 and 88.2% in mesh no: 24. The pellets were not even in 
size and irregular in shape and size. Maximum quantity of sample retained in mesh no: 
24. From trial F3-F6 the percentage of sample retained in mesh no 18 found to be 7.9, 
2.5, 1.9, and 1.4.  The size and shape of pellets were uniform. In mesh no: 20 the value 
ranges from 2.8 - 1.5 in mesh no: 24 the formulation F3, F4, F5 and F6 depicts the results 
of 89.3, 96.1, 97.1, and 97.0%. From the results the size of the pellets assumed to lie 
between 1.00mm - 0.710 µm as per U.S.P.  
The friability tests were performed in abrasive drum and the value ranges from 
0.964-0.160 .The values depicts friability is within and passes I.P limit which is not more 
than 1% w/w, indicating sufficient mechanical integrity and strength for prepared  pellets. 
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The value of loss on drying was checked for the formulations F2-F6. It ranges from 5.42-
0.97. Formulations   F4, F5 and F6 comply as per I.P limit which is less than 1%. 
Drug content of formulation F2-F6 was found to be 97.65, 97.86, 96.59, 99.45, 
and 101.80. The results shows all formulation containing drugs were within the limit (90-
110%) as per I.P and the results were given in the table no : 20 
TABLE 20: Evaluation of Core Pellets 
S.No FORMULATION F1 F2 F3 F4 F5 F6 
1 ANGLE OF REPOSE(degrees) - 52.56 43.61 30.68 27.12 26.56 
2 BULK DENSITY(gm/ml) - 0.588 0.645 0.714 0.754 0.749 
3 TAPPEDDENSITY(gm/ml) - 0.675 0.689 0.740 0.785 0.764 
4 CARR’S INDEX (%) - 22.94 16.45 10.57 9.09 8.98 
5 HAUSNER’S RATIO - 1.34 1.19 1.06 1.04 1.02 
6 LOSS ON DRYING (%) - 5.42 2.47 0.97 0.95 0.97 
7 FRIABILITY (%) - 0.964 0.521 0.266 0.197 0.160 
8 DRUG CONTENT (%) - 97.65 97.86 96.59 99.45 101.80 
 
TABLE 21: Sieve Analysis   for   Core Pellets 
S.NO SIEVE NO 
PERCENTAGE OF SAMPLE RETAINED IN EACH SIEVE 
F1 F2 F3 F4 F5 F6 
1. 18 - 8.4 7.9 2.5 1.9 1.4 
2. 20 - 3.4 2.8 1.4 1.0 0.97 
3. 24 - 88.2 89.3 96.1 97.1 98.03 
4. Pan - - - - - - 
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8.2.1. Evaluation of Diclofenac Sodium Capsules Filled With Core Pellets 
The pellets formulated from trial F2, F3, F4, F5 and F6 were filled into “1” size 
capsules in semi automatic machine. The weight variation tests were performed and the 
value lies between 401.3 ± 2.43 to 406.2 ± 2.23. The values are mentioned in table no: 22 
and observed to be within I.P Limit ± 5%. 
Assay was performed for randomly selected 10 capsules from each trial. The 
values range from 97.59-101.88. The results shows all the capsules of each trials 
containing drug were within the limit (90 - 110%) as per I.P. 
To ensure the consistency of dosage units, each unit should have drug content 
within a narrow range around   the label claim. Therefore test for content uniformity is 
performed. .Ten capsules randomly selected from each trial (F2-F6), Contents were 
removed and drug content present in each capsule is calculated. The average of ten 
capsules is calculated and values are given in table no: 22 the results show all the 
capsules were within the limit. (90-110%) as per I.P.  
The evaluation was continued with in-vitro dissolution studies.  Filled capsules 
were used for same. 
The formulation F2 with 24% MCC and 2% PVP K30 released 78.23% at 15 
minutes,84.25% at 30 minutes and 94.36% after 45 minutes .Formulation F3 with 28% 
MCC and 3% binder concentration showed 98.20% of drug release after 45 minutes.  
The dissolution data for formulation F4 with 32% of MCC and 4% PVP K30 
demonstrates 45.67% at 15 minutes, 63.45% at 30 minutes and 82.39% after 45 minutes. 
The release profile for formulation F5 was not satisfactory and it does not complies with 
IP limit  Therefore formulation F5 was tried by reducing the concentration of MCC to 
30% and PVPK30 to 3%.The drug is released 99.83% after 45 minutes. The results were 
confirmed by taking reproducibility batch F6 with 30% MCC and 3% binder 
concentration.  The results showed 99.21% at 15 minutes, 103.60% at 30 minutes and 
104.30% after 45 minutes. 
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The dissolution data for formulation F2-F6 were given in the table no: 23 and the 
values were plotted in graph: 3  
TABLE 22:  Evaluation of Diclofenac Sodium Capsules (F1-F6) 
S. 
No Formulations 
Weight        
variation in    (mg) ± 
S.D 
  Drug 
content(%) 
Cumulative % Content 
uniformity of 10 
capsules 
1. F1 - - - 
2. F2 401.3 ± 2.43 99.84 98.73 
3. F3 405.6 ± 3.04 97.59 97.45 
4. F4 405.3 ± 2.40 99.38 101.67 
5. F5 406.0 ± 2.18 99.40 99.05 
6. F6 406.2 ± 2.23 101.88 99.38 
 
TABLE 23: In-Vitro Release Study of Core Pellets (F1-F6) 
S.No Stage Time In 
Minutes 
Percentage Drug Release Of Core Pellets 
F1 F2 F3 F4 F5 F6 
1. BUFFER 
STAGE 
15 - 86.21 90.37 39.26 99.20 98.23 
2. 30 - 92.30 94.81 45.24 102.60 101.40 
3. 45 - 98.20 99.83 76.42 104.30 103.64 
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GRAPH: 3 In-Vitro Release Study of Core Pellets (F1-F6) 
 
8.3. Evaluation of Enteric Coated Pellets (C1-C8) 
Formulation C1- C8 was designed by enteric coating the core pellets of optimized 
formulation different enteric coating polymers such as Kollicoat MAE 100P and Eudragit 
L 100. The micromeritic properties such as bulk density, tapped density, angle of repose, 
hausner’s ratio, and Carr’s index were studied. The overall results were tabulated in table 
no: 24 
The angle of repose for the formulations C1-C8 ranges from 25.23o - 24.22o which 
depicts excellent flow character. Bulk density ranges from   0.714 gm/ml-0.820gm/ml. 
Tapped density for the enteric coated formulations C1-C8 lies between 0.732gm/ml-
0.859 gm/ml.  
Hausner’s ratio for enteric coated pellet formulations (C1-C8) ranges from 1.02 
gm/ml-1.10 m/ml .The values shows the property of excellent flow character. Percentage 
of Carr’s index for the formulations C1-C8 was found to be 2.40, 3.05, 2.67, 3.88, 8.98, 
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4.31, 9.17 and 5.00% respectively. These values demonstrates the excellent flow 
character of formulations C1-C8  
TABLE 24: Evaluation of Enteric Coated Pellets (C1-C8) 
 FORMULATION C1 C2 C3 C4 C5 C6 C7 C8 
ANGLE OF 
REPOSE 
(degrees) 
25.23 26.62 25.95 28.94 26.10 27.26 25.95 24.22 
BULK 
DENSITY(gm/ml) 0.714 0.746 0.764 0.792 0.816 0.734 0.812 0.820 
TAPPED 
DENSITY(gm/ml) 0.732 0.792 0.785 0.824 0.857 0.778 0.894 0.859 
CARR’S INDEX 
(%) 2.40 3.05 2.67 3.88 8.98 4.31 9.17 5.00 
HAUSNER’S 
RATIO 1.02 1.06 1.05 1.04 1.01 1.10 1.10 1.06 
LOSS ON DRYING 
(%) 0.79 0.85 0.94 0.97 0.96 0.90 0.85 0.97 
FRIABILITY (%) 0.214 0.175 0.326 0.563 0.459 0.523 0.143 0.965 
DRUG CONTENT 
(%) 101.05 97.65 95.76 101.67 99.32 99.45 101.84 107.71 
 
Sieve analysis   was performed in a sieve shaker with a set of sieves (18, 20, and 
24) to determine the particle size and its frequency of distribution. Percentage of sample 
retained in each sieve was calculated. As the pellets are enteric coated the size of the 
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pellets is slightly greater than the core pellets. This is evidently shown from the results 
tabulated in table no: 25 the percentage of sample retained in each sieve (18, 20, and 24) 
are greater than core pellets. The pellets are smooth and uniform. Maximum percentage 
of sample retained in sieve no: 24. From the results the size of the pellets lies between 
1.40-1.00 mm.  
The friability for coated pellets were checked and it ranges from 0.214-0.965% 
w/w and the values depicts friability is within IP limit which is not more than 1% w/w, 
indicating the sufficient mechanical integrity and strength of prepared pellets. 
Loss on drying for the formulations C1-C8 ranges from 0.79-0.97 % .The values 
were within 1% and complies within IP limit. 
Drug content of formulations C1-C8 was found to lie between   95.76%-
107.71%.the results shows all formulation containing drugs were within the limit (90-
110%) as per IP. 
TABLE 25: Sieve Analysis for Enteric Coated Pellets 
S.NO SIEVE NO  PERCENTAGE OF SAMPLE RETAINED IN EACH SIEVE (%) 
    C1      C2     C3     C4     C5    C6    C7    C8 
  1.              18    10.9    11.5   11.8    10.5   12.6   13.7   12.4    14.8 
  2.        20    23.9    30.4   30.0    31.9   47.8   49.3   48.2    50.6 
  3.        24    65.2    58.1   58.0    57.6    39.6   37.0   39.4   34.6 
  4.       Pan      -      -      -      -      -      -      -       - 
8.3.1. Evaluation of Diclofenac Sodium Enteric Coated Capsules (C1-C8) 
The enteric coated pellets were filled in “0” size capsules and checked for weight 
variation .The coating was done up to 15% of weight gain of total weight of core pellets. 
The average weight of each capsule ranges from 475.2± 1.17 – 478.3 ± 1.04. The 
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formulations C1-C8 was observed to be within I.P limit ± 5%. Their values are 
mentioned in table no: 26  
Assay was performed for randomly selected 10 capsules from each trial. The 
values range from 98.29-101.04. The results shows all the capsules of each trials 
containing drug were within the limit (90 - 110%) as per I.P. 
  To ensure the consistency of dosage units, each unit should have drug content 
within a narrow range around   the label claim. Therefore test for content uniformity is 
performed. .Ten capsules randomly selected from each trial (C1-C8), Contents were 
removed and drug content present in each capsule is calculated. The average of ten 
capsules is calculated and values are given in table no: 26 the results show all the 
capsules were within the limit. (90-110%) as per I.P. 
The dissolution studies for the formulations C1-C8 was performed in capsules 
filled with enteric coated pellets. 
8.3.2. In-Vitro Dissolution for Enteric Coated Capsules (C1-C8) 
The dissolution study was carried out in USP Type II dissolution apparatus. The 
samples were subjected to acid medium (0.1N HCl) for two hours and continued with pH 
6.8 phosphate buffer for 45 minutes. The samples were collected and checked for 
absorbance at 285 nm in UV-Spectrophotometer. 
The results were interpreted by plotting the graph with cumulative percentage 
drug release versus time in minutes in graph no: 4  
Formulation C1 enteric coated with 10% w/v of Kollicoat MAE 100P produced 
64.17% of release in acid medium. So, the formulation C2 was coated with 2% ethyl 
cellulose as seal coat to the pellets and 10% of enteric coating was done in combination 
to the seal coated pellets with Kollicoat MAE 100P the result was obtained as 39.85% of 
drug released within 2 hours in acid medium. To further reduce the drug release in acid 
medium the concentration of enteric coating polymer alone was increased as 15% with 
Kollicoat MAE 100P alone in the formulation C3, 59.92% of drug released, the result 
was improved when compared with C1 but worse than C2, Hence formulation C4 was 
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tried with 2% of seal coat in combination with 15% of Kollicoat MAE100P, and the 
acquired result was 29.93% of Diclofenac sodium release. Above results shows that, 
formulation C4 had quiet good improvement in the retarding of Diclofenac sodium 
release in 2 hours of acid medium when compared with the other formulation from C1 to 
C3, Even though desired drug retard with Kollicoat MAE 100P was not achieved. So, the 
alternate enteric coating polymer Eudragit L100 was decided to apply in the further 
formulation. 
Formulation C5 was coated with 10% of Eudragit L100 alone to the core pellets 
and the result was obtained as 24.65%. To retard the drug release more the formulation 
C6 was tried in the combination of 2% seal coat and 10% Eudragit L100 to the core 
pellets, the drug release was attained as 15.65%.To retard the drug release lesser than 
10% the concentration of Eudragit L100 alone increased to 15% in the formulation C7 
and sprayed to the core pellets, but the result was 11.63% which is not sufficient drug 
retard for the enteric coating dosage form. Hence, formulation C8 was tried with 2% seal 
coat and 15% Eudragit L100 and the Diclofenac sodium was released only 0.59% in the 
acid medium at 120th minute. 
From the above observation, formulation C1 to C6 does not complies with desired 
drug retard in the acid stage dissolution and the continuous buffer stage dissolution was 
not performed to it. Formulation C7 and C8 had a better drug retarding property so the 
process was carried to next continuous pH 6.8 phosphate buffer stage for 45 minutes. 
Formulation C7 shows 81.26% at 15th minute, 94.12% of drug release at 30th minute and 
98.80% at 45th minute. Formulation C8 shows 77.15%, 92.87% and 98.24% at 15, 30 and 
45 minutes respectively. 
When compared to C7, formulation C8 has shown negligible amount of  
Diclofenac sodium release in 0.1N HCl and almost maximum amount of drug releases in  
6.8 Phosphate Buffer which is the desired and optimum for the formulation of Diclofenac 
sodium enteric coated pellet dosage form.  
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TABLE 26:  Evaluation of Diclofenac Sodium Enteric Coated Capsules (C1-C8) 
S.No Formulations Weight        variation in (mg)  ± S.D 
Drug 
content 
(%) 
Cumulative % Drug 
content of 10 capsules 
1. C1 478.3 ± 1.04 99.56 99.73 
2. C2 476.0 ± 1.62 99.90 98.00 
3. C3 476.6  ± 1.20 98.29 100.60 
4. C4 475.9  ±1.11 99.08 101.88 
5. C5 475.2  ± 1.17 99.00 99.67 
6. C6 477.1  ±1.08 100.58 99.21 
7. C7 476.4 ± 0.99 101.04 101.98 
8. C8 476.5 ± 0.91 98.77 101.39 
 
TABLE 27: In-Vitro Evaluation of Enteric Coated Pellet Formulations (C1-C8) 
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GRAPH: 4 In-Vitro Release Study of Enteric Coated Pellets (C1-C8) 
 
 
S.NO  STAGE TIME IN 
MINUTES 
PERCENTAGE DRUG RELEASE OF ENTERIC 
COATED       PELLETS 
   C1         C2     C3   C4     C5   C6   C7    C8 
1. ACID STAGE 120 64.17 39.85 59.92 29.93 24.65 15.65 11.63 0.59 
2. 
BUFFER 
STAGE 
15 - - - - - - 81.26 77.15 
3. 30 - - - - - - 94.12 92.87 
4. 45 - - - - - - 98.80 98.24 
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8.4. Scanning Electron microscopy 
The particle size of core pellets ranges from 725.11µm- 961.82µ mm and the 
particle size of enteric coated pellets range from  1.19µm – 1.31 mm. The particle size of 
core pellets seems to be increased after coating process. These results are evident from 
SEM Photographs given in figure 17 & 18  
FIGURE 17: Scanning Electron Microscope Pictures of Diclofenac Sodium core 
pellets 
   
FIGURE 18: Scanning Electron Microscope Pictures of Diclofenac Sodium Enteric 
coated pellets  
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PHOTOGRAPHS OF DICLOFENAC SODIUM FILLED CAPSULES 
   
A) CORE PELLETS FILLED IN CAPSULES 
 
B) BLISTER PACKED ENTERIC COATED PELLETS FILLED IN CAPSULES  
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8.5. Stability studies of optimized pellet formulation (C8) 
Stability studies were conducted for the capsules with optimized pellet 
formulation (C8).The stability study was performed at 40°C ± 2° C / 75% RH for a 
specific time period. The capsules were analyzed for weight variation, friability, drug 
content, and invitro dissolution after a period of 30 and 60 days. The results obtained are 
shown in table no: 29 the formulation showed acceptable limit in weight variation, 
hardness, friability, thickness, drug content, and invitro dissolution. The overall results 
showed that the formulation is stable for a period of 60 days. Cumulative percentage of 
drug release was plotted in graph no: 5   
TABLE 28: Accelerated Stability Data of Capsule with Optimized Pellet 
Formulation (Storage Condition: 40°C/75%Rh) 
S.NO TESTS 
FIRST MONTH SECOND MONTH 
OPTIMIZED PELLET 
FORMULATION 
OPTIMIZED PELLET 
FORMULATION 
1. 
Capsule 
Description Orange/clear “1”size capsules. 
Orange/clear “1”size 
capsules. 
Pellet  
Description 
Orange colored spherical           
shaped enteric coated pellets. 
Orange colored spherical 
shaped enteric coated pellets. 
2. Average 
weight 476.4±1.04 475.2±0.99 
3. Weight 
variation 0.01% within the limit 0.03% within the limit 
4. Friability 0.54% within the limit 0.65% within the limit 
5. Drug content 99.69% 97.39% 
 
 
Table 29: In-Vitro Dissolution of Formulation C8 
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Invitro dissolution after 30 days at 40°c 
/ 75%rh 
Invitro dissolution after 60 days at 40°c / 
75%rh 
Dissolution   
medium 
Time in 
minutes 
Cumulative 
percentage 
drug release 
Dissolution   
medium 
Time in   
minutes 
Cumulative 
percentage 
drug release 
(%) 
0.1 N HCl 120 0.68 0.1N HCl 120 0.95 
Phosphate 
Buffer pH 
6.8 
15 95.35 
Phosphate 
Buffer pH 6.8 
15 87.45 
30 97.84 30 91.87 
45 99.84 45 97.45 
 
GRAPH: 5 After 30 &60 Days in Accelerated Stability Studies 
 
   
8.6. Comparison of Optimized Pellet Formulation C8 with Marketed Product: 
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The optimized formulation C8 was compared with marketed sample. The invitro 
dissolution of marketed sample was depicted in the table no: 30. Comparative invitro 
dissolution between optimized formulation C8 and marketed sample was plotted in graph 
no: 6. Marketed sample showed a cumulative release of 0.25% in acid medium and 
99.28% of Diclofenac sodium in buffer medium. Formulation C8 showed 0.69% of drug 
release in 0.1N HCl and 98.90% of drug in Phosphate Buffer pH 6.8. The overall result 
indicated formulation C8 is comparatively similar with marketed sample. 
 
Table no: 30 Comparative in-vitro dissolution of Optimized enteric coated pellet 
Formulation C8 Vs Marketed formulation: 
 
 
 S.no 
 
       
       Stage 
 
   
 Time in 
minutes 
 
             Percentage drug release (%) 
 
Optimized      
formulation(C8) 
 
Marketed 
formulation 
 
    1. 
 
 
 Acid    stage 
(0.1N Hcl) 
 
 
      120 
 
 
            0.69 
 
  
          0.27 
 
    2. 
 
 
 
Buffer stage 
(Phosphate               
Buffer Ph     
6.8) 
 
        15 
 
            90.65 
 
         92.74 
 
    3. 
 
        30 
 
           93.42 
 
         96.51 
 
    4. 
 
 
        45 
 
           98.90 
 
         99.28 
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GRAPH NO: 6 Comparative in-vitro dissolution of marketed sample Vs optimized 
pellet formulation (C8) 
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                                  9.SUMMARY AND CONCLUSION 
  
A present work attempts have been made to fabricate Diclofenac sodium enteric coated 
pellet  formulation by Extrusion-Marumerisation technique for the treatment of Osteo – 
Arthritis and Rheumatoid Arthritis. 
      Diclofenac sodium has been reported with GI Bleeding ,Ulceration and Perforation 
which can be fatal. So Diclofenac sodium was enteric coated with two different enteric 
coating polymers namely Kollicoat MAE 100P and Eudragit L 100 to retard the release in 
stomach and made available in intestine. 
      The core pellets were fabricated using Micro crystalline cellulose, Lactose 
monohydrate and Poly vinyl pyrolidone K30. Six trials was performed with different 
concentration of MCC,Lactose and PVP K30. Micrmeritic properties and dissolution 
profile were studied and among six trials F6 showed best results and considered to be 
optimized formulation. 
      The physical compatibility evaluation was performed in FTIR and DSC. The study 
complies that the drug, polymer and other excipients were physically compatible with 
each other.   
      
     The optimized formulation was taken for enteric coating. Eight trials were performed. 
C1-C4 is coated with 10% and 15% of Kollicoat MAE 100P using non–aqueous 
solvents.C2 and C4 is seal coated with 2% ethyl cellulose. Pellets were filled in “0” 
capsules and evaluated. The results failed the specifications of enteric coating. So, in 
further trials C5-C8 polymer was changed to Eudragit L 100.C5-C8 is coated with 10% 
and 15% polymer.C6 and C8 is seal coated with 2% ethyl cellulose and finally coated 
with Eudragit L 100. The final formulation C8 shows only 0.59% of drug release in acid 
media and 99..84% in buffer media. Finally diclofenac sodium enteric coated pellets with 
good retarding property in acid media and good release profile in buffer media is 
fabricated and evaluated. SEM analysis were performed for determining the particle size 
and surface characteristics of fabricated pellets. The coated pellets were greater in size 
when compared to Uncoated pellets. 
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CONCLUSION 
The present research work was carried out to prepare enteric coating pellet dosage form 
using Diclofenac sodium for the effective therapy in Osteoarthritis and Rheumatoid 
Arthritis. 
            Diclofenac sodium pellets were fabricated and enteric coated with two different 
polymers namely Eudragit L 100 and Kollicoat MAE 100P with different ratios. 
Diclofenac sodium enteric coated pellet formulation C8 with 2% seal coat of ethyl 
cellulose and 15% of Eudragit L l00 showed 0.59% in acid medium (0.1N HCL) and 
98.24% in Buffer medium (Phosphate buffer PH 6.8). 
From this research work it is evident that the formulated pellet formulation  has 
ability to retard  the release of diclofenac sodium  in stomach and made available in 
intestine, which shows similar drug release profile when compared to the marketed 
formulation.      
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